{
  "questions": [
    {
      "exact_answer": [
        [
          "Axial R"
        ],
        [
          "Fibroblasts"
        ],
        [
          "Phosphotransferases"
        ],
        [
          "Synovial"
        ],
        [
          "IRAK1 gene"
        ],
        [
          "RHEUMATOID ARTHRITIS (allelic variant)"
        ],
        [
          "Joints"
        ],
        [
          "Uridine"
        ],
        [
          "Synoviocytes"
        ],
        [
          "Generic Role"
        ],
        [
          "Synovial Membrane"
        ],
        [
          "Myofibroblasts"
        ],
        [
          "Reflecting"
        ],
        [
          "Contribution"
        ],
        [
          "Resident - Procedure Practitioner Identifier Code Type"
        ],
        [
          "Heterogeneity"
        ],
        [
          "Etanercept"
        ],
        [
          "cell type"
        ],
        [
          "Providing (action)"
        ],
        [
          "infliximab"
        ],
        [
          "Does play"
        ],
        [
          "geographic population"
        ],
        [
          "Response process"
        ],
        [
          "Rheumatoid Arthritis"
        ],
        [
          "macrophage"
        ],
        [
          "pathogenic aspects"
        ],
        [
          "Recombinant Cytokines"
        ],
        [
          "Proteins"
        ],
        [
          "HOXD9 gene"
        ],
        [
          "Monocytes"
        ],
        [
          "Ability"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "CCL18 gene"
        ],
        [
          "Negation"
        ],
        [
          "Continuance of life"
        ],
        [
          "Cells"
        ],
        [
          "Pivot Device Component"
        ],
        [
          "Triglyceride storage disease with ichthyosis"
        ],
        [
          "Homo sapiens"
        ],
        [
          "study of epigenetics"
        ],
        [
          "Singular"
        ],
        [
          "Type - attribute"
        ],
        [
          "Logical Condition"
        ],
        [
          "Migrated"
        ],
        [
          "Inflamed joint"
        ],
        [
          "Comprehension"
        ],
        [
          "Specimen Type - Polymorphonuclear neutrophils"
        ],
        [
          "Synovial joint structure"
        ],
        [
          "Synovial Fluid"
        ],
        [
          "Fluorescent stain method"
        ],
        [
          "Cigarette smoke (substance)"
        ],
        [
          "Supportive assistance"
        ],
        [
          "Investigates"
        ],
        [
          "Patient Condition Code - Stable"
        ],
        [
          "Entire articular cartilage"
        ],
        [
          "Links List"
        ],
        [
          "Lupus Erythematosus, Systemic"
        ],
        [
          "Subgroup"
        ],
        [
          "Distant"
        ],
        [
          "Specimen Type - Serum"
        ],
        [
          "Trait"
        ],
        [
          "Cartilage"
        ],
        [
          "DESTRUCTION JOINT"
        ],
        [
          "Massive"
        ],
        [
          "Mesenchymal Stem Cells"
        ],
        [
          "Requirement"
        ],
        [
          "Passive"
        ],
        [
          "cell-type specific apoptotic process"
        ],
        [
          "activate biological process"
        ],
        [
          "Blood Circulation"
        ],
        [
          "DNA Integration"
        ],
        [
          "CD4 Positive Memory T-Lymphocyte"
        ],
        [
          "Autoimmune reaction"
        ],
        [
          "Changed status"
        ],
        [
          "Stimulus"
        ],
        [
          "Cell Communication"
        ],
        [
          "consider"
        ],
        [
          "Image Feature"
        ],
        [
          "Cognitive function: initiation"
        ],
        [
          "Possibly Related to Intervention"
        ],
        [
          "Intermediate"
        ],
        [
          "Proportion"
        ],
        [
          "Network"
        ],
        [
          "Phenotype determination"
        ],
        [
          "findings aspects"
        ],
        [
          "Regulatory T-Lymphocytes"
        ],
        [
          "Inflammation"
        ],
        [
          "Differential quality"
        ],
        [
          "Induce (action)"
        ],
        [
          "Metabolic Inhibition"
        ],
        [
          "Unique"
        ],
        [
          "Double Value Type"
        ],
        [
          "Inflammatory disorder"
        ],
        [
          "Affect (mental function)"
        ],
        [
          "Behavior"
        ],
        [
          "Status"
        ],
        [
          "Activation action"
        ],
        [
          "Affected Area"
        ],
        [
          "Critical"
        ],
        [
          "Immune"
        ]
      ],
      "id": "52b2d405f828ad283c000009",
      "ideal_answer": "These rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints. Integration of GWAS results with cell-type specific gene expression or epigenetic marks have highlighted regulatory T cells and CD4 memory T cells as critical cell types in RA. we demonstrate that autoimmune patient (systemic lupus erythematosus and rheumatoid arthritis) serum activates both pDC and B cells, but IRAK1/4 kinase inhibition affects only the pDC response, underscoring the differential IRAK1/4 functional requirements in human immune cell. ur findings support the notion that heterogeneity between synovial tissues is reflected in FLS as a stable trait, and provide evidence of a possible link between the behavior of FLS and the inflammation status of RA synovium. Fibroblast-like synoviocytes (FLS) are resident mesenchymal cells of synovial joints that have been recognized to play an increasingly important role in the pathogenesis of rheumatoid arthritis (RA). it has been understood that resident, fibroblast-like cells contribute significantly to the perpetuation of disease, and that they may even play a role in its initiation. In RA patients, both etanercept and infliximab are able to induce cell type-specific apoptosis in the monocyte/macrophage population. "
    },
    {
      "id": "52b2f1014003448f5500000a",
      "ideal_answer": "Further analysis with array-CGH identified a mosaic 847 kb deletion in 15q11-q13, including SNURF-SNRPN, the snoRNA gene clusters SNORD116 (HBII-85), SNORD115, (HBII-52), SNORD109 A and B (HBII-438A and B), SNORD64 (HBII-13), and NPAP1 (C15ORF2). The imprinted Snurf-Snrpn chromosomal domain contains two large arrays of tandemly repeated, paternally expressed box C/D small-nucleolar RNA (snoRNA) genes: the SNORD115 (H/MBII-52) and SNORD116 (H/MBII-85) gene clusters believed to play key roles in the fine-tuning of serotonin receptor (5-HT2C) pre-mRNA processing and in the etiology of the Prader-Willi Syndrome (PWS), respectively. In addition, recently published data provide strong evidence in support of a role for the snoRNA SNORD116 cluster (HBII-85) in PWS etiology. Our previous translocation studies predicted a major role for the C/D box small nucleolar RNA cluster SNORD116 (PWCR1/HBII-85) in PWS. Identification and characterization of this case provide unequivocal evidence for a critical role for the SNORD116 snoRNA molecules in PWS pathogenesis. Our case adds further information about genotype-phenotype correlation and supports the hypothesis that SNORD116 plays a major role in the pathogenesis of Prader-Willi syndrome. Recent data suggest that snoRNA Snord116 is important for the pathogenesis of Prader-Willi syndrome (PWS) characterized by hyperphagia and obesity. "
    },
    {
      "exact_answer": [
        [
          "Muscular Dystrophy, Facioscapulohumeral"
        ],
        [
          "Autosomal dominant inheritance"
        ],
        [
          "Myopathy"
        ],
        [
          "Deoxyribonuclease EcoRI"
        ],
        [
          "Facial Paresis"
        ]
      ],
      "id": "52bf19c503868f1b06000001",
      "ideal_answer": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses. Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant muscular disorder associated with a short (\u003c35 kb) EcoRI/BlnI fragment resulting from deletion of an integral number of units of a 3.3-kb repeat located at 4q35. Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature. In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. "
    },
    {
      "exact_answer": [
        [
          "Muenke Syndrome"
        ],
        [
          "FGFR3 gene"
        ],
        [
          "MTSS1 gene"
        ],
        [
          "Craniosynostosis"
        ],
        [
          "ARID1B gene"
        ]
      ],
      "id": "52bf1d2e03868f1b0600000c",
      "ideal_answer": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. Muenke syndrome is characterized by various craniofacial deformities and is caused by an autosomal-dominant activating mutation in fibroblast growth factor receptor 3 (FGFR3(P250R)               ). The syndrome is defined molecularly by a unique point mutation c.749C\u003eG in exon 7 of the FGFR3 gene which results to an amino acid substitution p.Pro250Arg of the protein product. Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured. Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C\u003eG, encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3). Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. "
    },
    {
      "exact_answer": [
        [
          "peroxiredoxin 2"
        ],
        [
          "Enzymes"
        ],
        [
          "PRDX2 gene"
        ],
        [
          "Antioxidants"
        ],
        [
          "Hydrogen Peroxide"
        ]
      ],
      "id": "52bf1f1303868f1b06000014",
      "ideal_answer": "We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Peroxiredoxin 2 (PRDX2) has been known to act as an antioxidant enzyme whose main function is H(2)O(2) reduction in cells. These data indicate that Srx1 activity protects mice from the lethality of endotoxic shock, adding this enzyme to other host factors, as NRF2 and peroxiredoxin 2, which by regulating cellular reactive oxygen species levels act as important modifiers in the pathogenesis of sepsis. Peroxiredoxin 2 (Prx2), a thiol-dependent peroxidase, is the third most abundant protein in the erythrocyte, and its absence in knock-out mice gives rise to hemolytic anemia. The aim of this study was to examine gonadotropin regulation of antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats. Peroxiredoxin-2 (Prdx2), a potent peroxide reductant, is the third most abundant protein in the erythrocyte and might be expected to play a major role in the cell\u0027s oxidative defenses. Human erythrocyte peroxiredoxin 2 (Prx2) is a typical 2-cys cytosolic peroxiredoxin with thiol-dependent hydrogen peroxide scavenger activity. "
    },
    {
      "id": "52d8466298d0239505000006",
      "ideal_answer": "We report that low percentages of dimethylsulfoxide (DMSO) in liquid chromatography solvents lead to a strong enhancement of electrospray ionization of peptides, improving the sensitivity of protein identification in bottom-up proteomics by up to tenfold. Introducing to the 80% formic acid injection solution an organic solvent such as acetonitrile or acetonitrile-DMSO induced further retention selectivity,. "
    },
    {
      "exact_answer": [
        [
          "Heterochromatin"
        ],
        [
          "Lysine"
        ],
        [
          "Histone H3.3"
        ],
        [
          "histone modification"
        ],
        [
          "Massive"
        ],
        [
          "Negation"
        ],
        [
          "Immunoglobulins"
        ],
        [
          "Histone H4I"
        ],
        [
          "Chromosomes"
        ],
        [
          "Protein methylation"
        ],
        [
          "Deposition"
        ],
        [
          "Antibodies"
        ],
        [
          "suggestion"
        ],
        [
          "euchromatin location"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Enrich"
        ],
        [
          "diindolylmethane"
        ],
        [
          "Singular"
        ],
        [
          "Mus"
        ],
        [
          "Associated with"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Entire cell"
        ],
        [
          "Restricted"
        ],
        [
          "chromatin immunoprecipitation"
        ],
        [
          "Protein phosphorylation"
        ],
        [
          "Chromatin Ab"
        ],
        [
          "histone methylation"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Strong"
        ],
        [
          "Methyltransferase"
        ],
        [
          "histone methyltransferase"
        ],
        [
          "regional"
        ],
        [
          "Transcription, Genetic"
        ],
        [
          "Proteins"
        ],
        [
          "Tests (qualifier value)"
        ],
        [
          "Early"
        ],
        [
          "HIST3H3 gene"
        ],
        [
          "Reduced"
        ],
        [
          "H2AFZ gene"
        ],
        [
          "KRT9 gene"
        ],
        [
          "Preposition For"
        ],
        [
          "Experimental Result"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "chromocenter"
        ],
        [
          "Eukaryota"
        ],
        [
          "SUV39H1 gene"
        ],
        [
          "Structure of bilaminar embryo"
        ],
        [
          "SNRPN gene"
        ],
        [
          "Euchromatin"
        ],
        [
          "study of epigenetics"
        ],
        [
          "Mitotic Prophase"
        ],
        [
          "Histone Deacetylation"
        ],
        [
          "silence"
        ],
        [
          "Mitotic Anaphase"
        ],
        [
          "Hypermethylation"
        ],
        [
          "Study"
        ],
        [
          "Connect"
        ],
        [
          "Blastocyst structure"
        ],
        [
          "Interphase"
        ],
        [
          "Type - attribute"
        ],
        [
          "Labels (device)"
        ],
        [
          "Subfamily"
        ],
        [
          "Abnormally high"
        ],
        [
          "Diploid Cell"
        ],
        [
          "Generic Role"
        ],
        [
          "alternate pathway"
        ],
        [
          "DNA Microarray Chip"
        ],
        [
          "Spreading (qualifier value)"
        ],
        [
          "Immunoprecipitation"
        ],
        [
          "Investigates"
        ],
        [
          "Discriminate"
        ],
        [
          "Patient Condition Code - Stable"
        ],
        [
          "Reproducibility"
        ],
        [
          "Links List"
        ],
        [
          "Connective Tissue - Fibroblasts (MMHCC)"
        ],
        [
          "Initiate (source type)"
        ],
        [
          "combination of objects"
        ],
        [
          "Hereditary"
        ],
        [
          "histone lysine methylation"
        ],
        [
          "Arabidopsis"
        ],
        [
          "preference"
        ],
        [
          "Specialized"
        ],
        [
          "Tail"
        ],
        [
          "establishment and maintenance of localization"
        ],
        [
          "DNA Methylation Inhibition"
        ],
        [
          "DNA Methylation"
        ],
        [
          "Chromatin"
        ],
        [
          "Arm of chromosome"
        ],
        [
          "Mammals"
        ],
        [
          "parent"
        ],
        [
          "Embryo"
        ],
        [
          "Accepted"
        ],
        [
          "Maintaining (action)"
        ],
        [
          "Substance Use Domain"
        ],
        [
          "Fibroblasts"
        ],
        [
          "Adjacent"
        ],
        [
          "Y Chromosome"
        ],
        [
          "classical example"
        ],
        [
          "Embryonic Stem Cells"
        ],
        [
          "2+ Score"
        ]
      ],
      "id": "52e0c9a298d0239505000010",
      "ideal_answer": "Remarkably, in mammalian somatic cells, H3S10P initiates in the pericentromeric heterochromatin during the late G2 phase, and phosphorylation spreads throughout the chromosomes arms in prophase, being maintained until the onset of anaphase when it gets dephosphorylated. 3S10 phosphorylation marks constitutive heterochromatin during interphase in early mouse embryos until the 4-cell stage. Based on these findings, we believe that H3S10P is a good marker of pericentromeric heterochromatin, especially in the late 1- and 2-cell stages as it labels both parental genomes and that it can be used to further investigate epigenetic regulation and heterochromatin mechanisms in early preimplantation embryos. We show here that the maternally inherited Snurf-Snrpn 3-Mb region, which is silenced by a potent transcription repressive mechanism, is uniformly enriched in histone methylation marks usually found in constitutive heterochromatin, such as H4K20me3, H3K9me3, and H3K79me3. We show that H3K36me3 deposition within this large heterochromatin domain does not correlate with transcription events, suggesting the existence of an alternative pathway for the deposition of this histone modification. In addition, we demonstrate that H3K36me3 is markedly enriched at the level of pericentromeric heterochromatin in mouse embryonic stem cells and fibroblasts. "
    },
    {
      "exact_answer": [
        [
          "Life Expectancy"
        ],
        [
          "Athletes"
        ],
        [
          "Heart"
        ],
        [
          "Sports"
        ],
        [
          "Aerobic"
        ]
      ],
      "id": "52e62bae98d0239505000015",
      "ideal_answer": "Competitive exercise does not induce cardiac damage in individuals with healthy hearts, but does induce physiological functional and structural cardiac adaptations which have positive effects on life expectancy. It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. In conclusion, while regular physical activity increases life expectancy, it remains unclear if high-intensity sports activities further increase life expectancy. Lower cardiovascular disease mortality is likely the primary reason for their better survival rates. On the other hand, there are inconsistent results among studies of power (anaerobic) athletes. "
    },
    {
      "exact_answer": [
        [
          "Genetic Hotspot"
        ],
        [
          "Codon Genus"
        ],
        [
          "KRAS gene"
        ],
        [
          "Mutation"
        ],
        [
          "K-ras Oncogene"
        ],
        [
          "Homo sapiens"
        ],
        [
          "HRAS wt Allele"
        ],
        [
          "N not otherwise specified Antibody"
        ],
        [
          "Exons"
        ],
        [
          "Proteins"
        ],
        [
          "Arabic numeral 31"
        ],
        [
          "Integer +2"
        ],
        [
          "TP53 gene"
        ],
        [
          "Protons"
        ],
        [
          "K Prime"
        ],
        [
          "Sector"
        ],
        [
          "Hot Spot"
        ],
        [
          "Neoplasm"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Tumors of Adrenal Cortex"
        ],
        [
          "Repeat"
        ],
        [
          "Analysis of substances"
        ],
        [
          "are unit of measure"
        ],
        [
          "Occur (action)"
        ],
        [
          "Function"
        ],
        [
          "Three"
        ],
        [
          "Analysis"
        ],
        [
          "Study"
        ]
      ],
      "id": "52e6c92598d0239505000019",
      "ideal_answer": "the mutation hotspots of the K-ras proto-oncogene in human functional adrenocortical tumors are in codons 15, 16, 18, and 31. mutations C742T, G746T, G747T in the TP53 gene and G35T in the KRAS gene have been repeatedly found in sectors of human tumors. In this study we analyzed 15 sMTC for mutations in the hotspots codon 12, 13 and 61 of the H- and K-ras oncogene. three hotspots in KRAS (codons 12/13, 61 and 146). mutations occurring in mutational hotspots (codons 12 and 13) of the KRAS protein. and N-, K-, and H-RAS (codons 12, 13, and 61). mutation in the codon 12, 13 and 61 of the H-ras and K-ras oncogene. exons 1 and 2 of KRAS. KRAS (codon 12/13 hotspot). analysis of KRAS (codon12/13). "
    },
    {
      "exact_answer": "yes",
      "id": "52e7870a98d023950500001a",
      "ideal_answer": "Our data depict a model that can reconcile the conflicting observations on the functional impact of the C1858T SNP and also suggest that PTPN22.6 is a novel biomarker of rheumatoid arthritis. Cox proportional hazards regression models were used to assess the association of the HLA-DRB1 (including the shared epitope [SE]) and PTPN22 genes with the risk of death from all causes and from cardiovascular disease (CVD) and to assess the interactions between SE, smoking, and anti-cyclic citrullinated peptide (anti-CCP) status, adjusted by age at symptom onset and sex. However, inconsistent results of the contributions of non-HLA susceptibility genes have been described, with the exception of a few genes repeatedly associated with RA-susceptibility, such as PTPN22 gene in populations of European ancestry and PADI4 gene in populations of Asian ancestry, revealing the presence of genetic heterogeneity in RA. Analyses of families with multiple autoimmune disorders have revealed a functional polymorphism, 620W, in the intracellular tyrosine phosphatase gene PTPN22 as a predisposing factor for type 1 diabetes, seropositive rheumatoid arthritis, systemic lupus erythematosus, and Hashimoto thyroiditis, and the presence of the PTPN22 protein appears to herald the development of autoantibodies in these disorders. "
    },
    {
      "exact_answer": "yes",
      "id": "52e7b4a198d023950500001b",
      "ideal_answer": "Thyroid hormones exert important effects on heart remodeling through mir-208. These results suggest that long-term T4 treatment after MI has beneficial effects on myocyte, arteriolar, and collagen matrix remodeling in the non-infarcted area. Most importantly, results suggest improved survival of myocytes in the peri-infarct area. l-T4 therapy and 1-year maintenance of euthyroid status improved but did not completely recover RV and RA function and deformation in the SHT patients, which implies that right heart remodeling caused by SHT is not reversible in a 1-year period. RV and RA function and mechanics are significantly affected by SHT. "
    },
    {
      "exact_answer": [
        [
          "Calsequestrin"
        ],
        [
          "CASQ2 gene"
        ],
        [
          "RYR2 gene"
        ],
        [
          "Encode (action)"
        ],
        [
          "Mutation"
        ],
        [
          "Cardiac - anatomy qualifier"
        ],
        [
          "CALR3 gene"
        ],
        [
          "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1 (disorder)"
        ],
        [
          "Genes"
        ],
        [
          "Etiology aspects"
        ],
        [
          "KCNJ2 gene"
        ],
        [
          "Gene Mutation"
        ],
        [
          "SRI gene"
        ],
        [
          "Hereditary Diseases"
        ],
        [
          "Calcium"
        ],
        [
          "Associated with"
        ],
        [
          "Exons"
        ],
        [
          "Heart"
        ],
        [
          "Relationships"
        ],
        [
          "Formation"
        ],
        [
          "Proteins"
        ],
        [
          "CALM1 gene"
        ],
        [
          "Sudden Death Adverse Event Not Associated with More Specific CTCAE Term"
        ],
        [
          "Pivot Device Component"
        ],
        [
          "inward rectifier potassium channel 2"
        ],
        [
          "Sarcoplasmic Reticulum"
        ],
        [
          "Infrequent"
        ],
        [
          "Autosomal recessive inheritance"
        ],
        [
          "Cardiac Arrest"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Variant"
        ],
        [
          "Distal"
        ],
        [
          "Date in time"
        ],
        [
          "Health maintenance"
        ],
        [
          "Pathogenesis"
        ],
        [
          "Genetic screening method"
        ],
        [
          "Behavior"
        ],
        [
          "Release - action (qualifier value)"
        ],
        [
          "Regulation of biological process"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "MT-TD gene"
        ],
        [
          "Disease"
        ],
        [
          "\u003c3 (qualifier value)"
        ]
      ],
      "id": "52e8e98298d0239505000020",
      "ideal_answer": "mutations in the gene encoding for cardiac calsequestrin, CASQ2, cause a rare but severe form of catecholaminergic polymorphic ventricular tachycardia (CPVT). The disease is associated with mutations in the genes encoding for the cardiac ryanodine receptor (RyR2) and cardiac calsequestrin (CASQ2). Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease so far related to mutations in the cardiac ryanodine receptor (RYR2) or the cardiac calsequestrin (CASQ2) genes. CPVT can be caused by mutations the cardiac ryanodine receptor gene (RYR2) or mutations in the cardiac calsequestrin gene CASQ2. mutations in RYR2-encoded ryanodine receptor 2, CASQ2-encoded calsequestrin 2, CALR3-encoded calreticulin 3, and SRI-encoded sorcin have been associated with HCM. These proteins are pivotal to the regulation of calcium release from the sarcoplasmic reticulum, and mutations can cause CPVT. genetic testing was conducted in all exons on 3 CPVT-related genes: cardiac ryanodine receptor 2 (RYR2), calsequestrin 2 (CASQ2) and inward rectifier potassium channel 2 (KCNJ2),. To date, about 189 variants in 5 genes (RYR2, CASQ2, CALM1, TRND, and KCNJ2) have been associated with CPVT pathogenesis. The autosomal recessive form of CPVT is caused by mutations in the CASQ2 gene. "
    },
    {
      "exact_answer": "yes",
      "id": "52e8e99e98d0239505000021",
      "ideal_answer": "Case reports on abatacept, tocilizumab or anakinra in pregnancy are not conclusive. Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept. The very limited experience with abatacept, tocilizumab or anakinra in pregnancy allows no statement as to their compatibility with pregnancy. Pregnancy experience with abatacept and rituximab is still too limited to prove their safety for the developing fetus. As such, it is recommended that abatacept, rituximab and tocilizumab be withheld prior to pregnancy;. Prophylactic withdrawal of drugs before pregnancy is mandatory for abatacept,. Their use is not currently allowed during pregnancy except in cases where the potential benefit to the mother justifies the potential risk to the fetus. Methotrexate and biotherapies have demonstrated no effect on fertility; however these drugs must be stopped before conception for a period equal to seven fold of the half live of the molecule. The risk for some of the newer biological therapies for RA is not necessarily their proven teratogenicity, but the absence of proven safety for the fetus. Biologics should be avoided unless there is a treatment need in cases of uncontrolled disease activity. "
    },
    {
      "exact_answer": [
        [
          "Tuberous Sclerosis"
        ],
        [
          "Pulmonary lymphangioleiomyomatosis"
        ],
        [
          "Cardiac - anatomy qualifier"
        ],
        [
          "Type - attribute"
        ],
        [
          "TSC1-TSC2 complex location"
        ],
        [
          "Subependymal Giant Cell Astrocytoma"
        ],
        [
          "elliptinium"
        ],
        [
          "NMI gene"
        ],
        [
          "shared attribute"
        ],
        [
          "Lymphangioleiomyomatosis"
        ],
        [
          "Frequent"
        ],
        [
          "clinical aspects"
        ],
        [
          "Angiomyolipoma of kidney"
        ],
        [
          "Woman"
        ],
        [
          "incidence of cases"
        ],
        [
          "Benign Neoplasm"
        ],
        [
          "Sporadic"
        ],
        [
          "Cortical Dysplasia"
        ],
        [
          "Qualitative form"
        ],
        [
          "Patients"
        ],
        [
          "Internal-External Locus of Control Scale"
        ],
        [
          "Associated with"
        ],
        [
          "Relationships"
        ],
        [
          "CLYBL gene"
        ],
        [
          "Mutation"
        ],
        [
          "Prevalence aspects"
        ],
        [
          "Young"
        ],
        [
          "CDISC SEND Tumor Findings Results Terminology"
        ],
        [
          "Neurologic (qualifier value)"
        ],
        [
          "Seizures"
        ],
        [
          "CCL26 wt Allele"
        ],
        [
          "Fleck corneal dystrophy"
        ],
        [
          "Hemimegalencephaly"
        ],
        [
          "Rhabdomyoma"
        ],
        [
          "Angiofibroma"
        ],
        [
          "Neuraxis"
        ],
        [
          "TSC2 gene"
        ],
        [
          "neurofibroma"
        ],
        [
          "Cortical tubers"
        ],
        [
          "Hamartoma"
        ],
        [
          "Genus Tuber (fungus)"
        ],
        [
          "Chronic bullous emphysema"
        ],
        [
          "Body Site Modifier - Lower"
        ],
        [
          "Mucous Membrane"
        ],
        [
          "Clinical trial participant (person)"
        ],
        [
          "Plant nodule"
        ],
        [
          "Infrequent"
        ],
        [
          "Generic Role"
        ],
        [
          "Histopathology"
        ],
        [
          "neurologic sequelae"
        ],
        [
          "Heart Neoplasm"
        ],
        [
          "Common Neoplasm"
        ],
        [
          "Medical Balloon Device"
        ],
        [
          "Cortical malformations"
        ],
        [
          "Focal dysplasia"
        ],
        [
          "Lung cyst"
        ],
        [
          "Mental Retardation"
        ],
        [
          "Skin Specimen"
        ],
        [
          "Various patch test substance"
        ],
        [
          "neuron migration"
        ],
        [
          "Refractory epilepsy"
        ],
        [
          "Epilepsy"
        ],
        [
          "Started"
        ],
        [
          "Reporting"
        ],
        [
          "Adrenal Cortex"
        ],
        [
          "Lethal"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Diffuse"
        ],
        [
          "Focal"
        ],
        [
          "True"
        ],
        [
          "consider"
        ],
        [
          "Feature"
        ],
        [
          "Image Feature"
        ],
        [
          "Cohort"
        ],
        [
          "Bilateral"
        ],
        [
          "Smaller"
        ],
        [
          "Study Subject"
        ],
        [
          "Subject Characteristics Domain"
        ],
        [
          "Pneumothorax, recurrent"
        ],
        [
          "Image Study"
        ],
        [
          "Characterization"
        ],
        [
          "Organ"
        ],
        [
          "Progressive"
        ],
        [
          "Numbers"
        ],
        [
          "respiratory function impaired"
        ],
        [
          "Variable (uniformity)"
        ],
        [
          "Abnormal"
        ],
        [
          "Kidney finding"
        ],
        [
          "Finding of brain"
        ],
        [
          "development aspects"
        ],
        [
          "Differential Diagnosis"
        ],
        [
          "Magnetic Resonance Imaging"
        ],
        [
          "Reviewed"
        ],
        [
          "Unknown"
        ],
        [
          "Functional disorder"
        ],
        [
          "Affect (mental function)"
        ],
        [
          "Behavior Disorders"
        ],
        [
          "Comparison"
        ],
        [
          "Does play"
        ],
        [
          "Rare"
        ]
      ],
      "id": "52ebb2c698d0239505000029",
      "ideal_answer": "Rhabdomyoma is the most common type of cardiac tumor in fetuses and is often associated with tuberous sclerosis complex (TSC) with neurologic sequelae. Balloon cells are histopathological hallmarks of various cortical malformations, i.e., focal cortical dysplasia (Taylor\u0027s type, FCD IIb), hemimegalencephaly (HME) or cortical tubers (tuberous sclerosis, TSC). Pulmonary lymphangioleiomyomatosis is a rare cause of recurrent pneumothorax and should be considered a differential diagnosis, especially in young women with diffuse bilateral bullous emphysema or tuberous sclerosis. Lymphangioleiomyomatosis (LAM) is a rare, progressive, frequently lethal cystic lung disease that almost exclusively affects women. clinical characteristics of subjects with pulmonary lymphangioleiomyomatosis, both sporadic and tuberous sclerosis-related forms. Prevalence and long-term outcome of epilepsy in tuberous sclerosis complex (TSC) is reported to be variable. Women with tuberous sclerosis-related lymphangioleiomyomatosis were younger and had less impaired lung function compared with those with the sporadic form. NMI patients had a lower incidence of brain findings on imaging studies, neurological features, and renal findings than those with TSC2 mutations. In contrast, NMI patients had a lower incidence of seizures than TSC patients with TSC1 mutations, but had a higher incidence of both renal angiomyolipomas and pulmonary lymphangioleiomyomatosis. "
    },
    {
      "exact_answer": "yes",
      "id": "52ecd56198d023950500002b",
      "ideal_answer": "Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor. Mutations in human TRα1 mediate RTH with features of hypothyroidism in particular tissues (e.g. skeleton, gastrointestinal tract), but are not associated with a markedly dysregulated pituitary-thyroid axis. "
    },
    {
      "exact_answer": [
        [
          "Replication Origin"
        ],
        [
          "Archaea"
        ],
        [
          "Plasmids"
        ],
        [
          "Singular"
        ],
        [
          "Numerous"
        ]
      ],
      "id": "52ef7786c8da898910000015",
      "ideal_answer": "However, because some archaeal genomes contain multiple origins of replication, bias in gene dosage caused by delayed replication should be minimized and hence the substitution rate of genes should associate less with chromosome position. We draw the conclusion that multiple functional sites of origin of replication may exist in the genomes of most archaea and in some exceptional cases of eubacteria, while in the majority of eubacteria, replication occurs through a single fixed origin. Replication starts at a single Ori site in bacteria, but in eukaryotes multiple Ori sites are used for fast copying across all chromosomes. In the process of identifying the minimum replication origin sequence required for autonomous plasmid replication in P. furiosus, we discovered that several features of the origin predicted by bioinformatic analysis and in vitro binding studies were not essential for stable autonomous plasmid replication. In the present study we show that a previously identified cluster of ORB (origin recognition box) sequences do indeed function as an origin of replication in vivo in the archaeon Methanothermobacter thermautotrophicus. "
    },
    {
      "exact_answer": [
        [
          "Thyroxine"
        ],
        [
          "Synthetic Levothyroxine"
        ],
        [
          "Abnormally high"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Replacement therapy"
        ]
      ],
      "id": "52efbfccc8da898910000018",
      "ideal_answer": "Treatment of SCH with levothyroxine was associated with fewer IHD events in younger individuals, but this was not evident in older people. Sustained normalization of thyroid function during l-T(4) replacement therapy significantly decreases baPWV in female subclinical hypothyroid patients with autoimmune chronic thyroiditis, suggesting the improvement of arterial stiffening and, consequently, possible prevention of cardiovascular disease. The decision to treat elderly people is still an unresolved clinical challenge--first, due to a lack of appropriately powered randomized controlled trials of L-T4 in sHT patients, examining cardiovascular hard endpoints in various classes of age; and second, because of the negative effects of possible overtreatment. Although a consensus is still lacking, the strongest evidence for a beneficial effect of levothyroxine replacement on markers of cardiovascular risk is the substantial demonstration that restoration of euthyroidism can lower both total and low-density lipoprotein-cholesterol levels in most patients with subclinical hypothyroidism. Restoration of euthyroidism by levothyroxine (LT4) treatment may correct the lipid profile and cardiac abnormalities, especially in patients with an initially higher deviation from normality and higher serum TSH levels. However, it is still unproven whether preoperative thyroxine replacement therapy for patients with SCH might prevent postoperative atrial fibrillation after CABG. "
    },
    {
      "exact_answer": "yes",
      "id": "52efc001c8da898910000019",
      "ideal_answer": "The mean oxaluric response to an oxalate load is markedly elevated in post-bariatric surgery patients, suggesting that increased intestinal absorption of dietary oxalate is a predisposing mechanism for enteric hyperoxaluria. Despite the fact that bariatric surgery-induced weight loss is associated with a significant decrease in morbidity and mortality and improvement in renal function, bariatric surgery has recently been shown to be associated with a significant risk of nephrolithiasis. Therefore, after bariatric surgery, increases in fecal fat excretion, urinary oxalate excretion after an oral oxalate load, plasma oxalate, and urinary calcium oxalate supersaturation values were observed. The main risk factor for nephrolithiasis is increased excretion of urinary oxalate. Hyperoxaluria and increased calcium oxalate stone formation occur after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity. Persistent mild to moderate hyperoxaluria (PMMH) is a common side effect of bariatric surgery. Our study confirms the risk of urinary stones following the Roux-en-Y gastric bypass procedure as a result of hyperoxaluria, low urine volume and hypocitraturia. This prospective study indicates that RYGB is associated with an earlier increase in urinary oxalate excretion and relative supersaturation of calcium oxalate than previously reported. "
    },
    {
      "exact_answer": "yes",
      "id": "52efc05cc8da89891000001c",
      "ideal_answer": "Resveratrol treatment does not improve cardiac remodeling and global hemodynamic function post-MI but does preserve contractile reserve and attenuate ANF and CTGF up-regulation. These results suggested that the emerging anti-arrhythmic character induced by resveratrol treatment in rat hearts could be mainly accounted for by inhibition of I (Ca-L) and enhancement of I (K,ATP). Our findings suggest that the beneficial effects of SIRT1 activator resveratrol on Ang II-induced cardiac remodeling are mediated by blood pressure-dependent pathways and are linked to increased mitochondrial biogenesis. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. In conclusion, resveratrol is a beneficial pharmacological tool that augments autophagy to bring about reverse remodeling in the postinfarction heart. Administration of resveratrol also improved the long-term survival by suppressing left ventricular remodeling. Resveratrol alleviates the deleterious effects of fractalkine on myocardial ischemia and thus reduces subsequent cardiac remodeling. "
    },
    {
      "id": "52f3a9ef2059c6d71c000012",
      "ideal_answer": "To investigate whether transmyocardial drilling revascularization combined with heparinized basic fibroblast growth factor (bFGF)-incorporating degradable stent implantation (TMDRSI) can promote myocardial regeneration after acute myocardial infarction. Support to the paracrine hypothesis is provided by data showing that several genes, coding for factors (VEGF, FGF-2, HGF, IGF-I, and TB4) that are potential mediators of the effects exerted by the Akt-MSC conditioned medium, are significantly up-regulated in the Akt-MSCs, particularly in response to hypoxia. Exogenous bFGF was shown to have increased angiogenesis and myocardial perfusion, promoted myocardial regeneration by activating the SDF-1α/CXCR4 axis, and thereby improved the cardiac function, which may provide a new therapeutic strategy for AMI. The new method has shown to be capable of promoting CSCs proliferation and differentiation into cardiomyocytes through activating the SDF-1/CXCR4 axis, while inhibiting myocardial apoptosis, thereby enhancing myocardial regeneration following AMI and improving cardiac function. Taken together, our data support Akt-MSC-mediated paracrine mechanisms of myocardial protection and functional improvement. Prevascularization with basic fibroblast growth factor-incorporated microspheres enhances the benefits of cardiomyocyte transplantation. We expect that this system will contribute to regeneration medicine through its extensive application to other growth factors. "
    },
    {
      "exact_answer": [
        [
          "Cardiomyopathies"
        ],
        [
          "Negation"
        ],
        [
          "LDB3 gene"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Associated with"
        ],
        [
          "Wooly hair"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "TNNT2 wt Allele"
        ],
        [
          "Genes"
        ],
        [
          "MYH7 gene"
        ],
        [
          "Proteins"
        ],
        [
          "Acantholytic"
        ],
        [
          "Patients"
        ],
        [
          "Cardiomyopathy dilated with Woolly hair and keratoderma"
        ],
        [
          "Palmoplantar Keratosis"
        ],
        [
          "MUT gene"
        ],
        [
          "Homozygote"
        ],
        [
          "Heterozygote"
        ],
        [
          "Online Mendelian Inheritance In Man"
        ],
        [
          "suggestion"
        ],
        [
          "Racial Segregation"
        ],
        [
          "Congestive heart failure"
        ],
        [
          "Dilated"
        ],
        [
          "Supportive assistance"
        ],
        [
          "Confirmation"
        ],
        [
          "Myocardium"
        ],
        [
          "Encode (action)"
        ],
        [
          "Bed Status - Isolated"
        ],
        [
          "Protein Isoforms"
        ],
        [
          "CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 1 (disorder)"
        ],
        [
          "Familial"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Genetic Heterogeneity"
        ],
        [
          "Qualitative form"
        ],
        [
          "Etiology"
        ],
        [
          "Feature"
        ],
        [
          "regional"
        ],
        [
          "Skeletal system"
        ],
        [
          "newly"
        ],
        [
          "Classification"
        ],
        [
          "Concept Relationship"
        ],
        [
          "Health maintenance"
        ],
        [
          "Conclusion"
        ],
        [
          "Contain (action)"
        ],
        [
          "Phenotype determination"
        ],
        [
          "Left ventricular structure"
        ],
        [
          "Spectrum"
        ],
        [
          "Novel Mutation"
        ],
        [
          "Mutation"
        ],
        [
          "% index"
        ],
        [
          "Adult onset"
        ],
        [
          "Laboratory mice"
        ],
        [
          "Patient Physiological Condition"
        ],
        [
          "Component (part)"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Experimental Result"
        ],
        [
          "Molecular"
        ],
        [
          "Identified"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Early-onset"
        ]
      ],
      "id": "52f637972059c6d71c000025",
      "ideal_answer": "Familial co-segregation and the cardiomyopathy phenotype of mut cTNT mice strongly support a causal relationship of the pE96K mutation and disease in our index patient. Conclusion These results confirm the genetic heterogeneity of NCCM and suggest that the molecular classification of cardiomyopathies includes an MYH7-associated spectrum of NCCM with HCM, RCM, and DCM. This novel homozygous truncating mutation in the isoform-1 specific region of the DSP C-terminus caused Carvajal syndrome comprising severe early-onset heart failure with features of non-compaction cardiomyopathy, woolly hair and an acantholytic form of palmoplantar keratoderma in our patient. This mutation had been previously associated with an adult-onset, isolated, dilated left ventricular non-compaction cardiomyopathy (OMIM*605906.0007),. Cypher/ZASP is a newly identified gene encoding a protein that is a component of the Z-line in both skeletal and cardiac muscle. The heterozygous mutation c.349G\u003eA (p.D117N) in the ZASP gene could be found. which was not present in our patients. "
    },
    {
      "exact_answer": [
        [
          "P prime"
        ],
        [
          "PPARgamma2"
        ],
        [
          "Thyrotropin Receptor"
        ],
        [
          "Iodide Peroxidase"
        ],
        [
          "Iodothyronine Deiodinase"
        ],
        [
          "Human Study Subject"
        ],
        [
          "Genetic Carriers"
        ],
        [
          "Hypertensive (finding)"
        ],
        [
          "Actual Positive Blood Pressure"
        ],
        [
          "Metabolic Syndrome X"
        ],
        [
          "Blood Pressure"
        ],
        [
          "Type 2"
        ],
        [
          "DIO2 gene"
        ],
        [
          "Diastole"
        ],
        [
          "Systole"
        ],
        [
          "Associated with"
        ],
        [
          "Worst"
        ],
        [
          "Specimen Type - Serum"
        ],
        [
          "Component object"
        ],
        [
          "Modulated"
        ],
        [
          "Hypertensive disease"
        ],
        [
          "Observation parameter"
        ],
        [
          "Excess"
        ],
        [
          "Genetic Polymorphism"
        ],
        [
          "Polymorphism"
        ],
        [
          "Variant"
        ],
        [
          "Thyroid Gland"
        ],
        [
          "Elderly (population group)"
        ],
        [
          "Obesity, Abdominal"
        ],
        [
          "Phenotype"
        ],
        [
          "Blood pressure finding"
        ],
        [
          "Comparison"
        ],
        [
          "gene interaction"
        ],
        [
          "Gene Frequency"
        ],
        [
          "large group"
        ],
        [
          "Presence"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Observed"
        ]
      ],
      "id": "52f65bf02059c6d71c000026",
      "ideal_answer": "In two large populations of elderly subjects, neither serum thyroid parameters nor polymorphisms in the type 2 deiodinase and the TSH receptor, were associated with blood pressure or the presence of hypertension. Type 2 iodothyronine deiodinase Thr92Ala allele frequencies differed significantly between hypertensive and normotensive subjects, with an excess of Ala92 carriers in hypertensive compared with normotensive subjects (64.8% versus 47.1%; P\u003d0.011). A significant gene-gene interaction was observed in the modulation of systolic (p \u003d 0.01) and diastolic (p \u003d 0.02) blood pressure and metabolic syndrome (p \u003d 0.02), with carriers of both DIO2 A92 and PPARgamma2 A12 variants showing the worst phenotype. However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity. "
    },
    {
      "exact_answer": [
        [
          "Base - General Qualifier"
        ],
        [
          "sensor (device)"
        ],
        [
          "Home environment"
        ],
        [
          "Device Component System"
        ],
        [
          "Phonocardiography"
        ],
        [
          "Telemetry"
        ],
        [
          "Congestive heart failure"
        ],
        [
          "Biomedical Monitors"
        ],
        [
          "Transmitted by"
        ],
        [
          "Blood pressure finding"
        ],
        [
          "Helping Behavior"
        ],
        [
          "Personal failure"
        ],
        [
          "Remote"
        ],
        [
          "concept"
        ],
        [
          "Preposition For"
        ],
        [
          "Preventive monitoring"
        ],
        [
          "Taking vital signs"
        ],
        [
          "Patients"
        ],
        [
          "Feasibility Studies"
        ],
        [
          "algorithm"
        ],
        [
          "Cardiotochogram"
        ],
        [
          "KCNIP3 gene"
        ],
        [
          "Hyperglycemia"
        ],
        [
          "Design"
        ],
        [
          "Signal"
        ],
        [
          "Tights"
        ],
        [
          "Mobile"
        ],
        [
          "TCAP gene"
        ],
        [
          "subscriber - self"
        ],
        [
          "disease transmission qualifier"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Ambulatory - qualifier value"
        ],
        [
          "Reading (activity)"
        ],
        [
          "FOXD3 gene"
        ],
        [
          "Observation parameter"
        ],
        [
          "Shirt"
        ],
        [
          "Negation"
        ],
        [
          "adventure"
        ],
        [
          "Dangerousness"
        ],
        [
          "Ambulances"
        ],
        [
          "Delaware"
        ],
        [
          "Providing (action)"
        ],
        [
          "Textiles"
        ],
        [
          "Tonsillectomy and adenoidectomy"
        ],
        [
          "Paper Authorization"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Biomedicine"
        ],
        [
          "Desiccation"
        ],
        [
          "Polysomnography"
        ],
        [
          "Clothing"
        ],
        [
          "Disasters"
        ],
        [
          "Electrocardiography"
        ],
        [
          "server (role)"
        ],
        [
          "Implantable defibrillator"
        ],
        [
          "Singular"
        ],
        [
          "Mobile Phone"
        ],
        [
          "Emergencies [Disease/Finding]"
        ],
        [
          "Bone Wires"
        ],
        [
          "Vital High Nitrogen Enteral Nutrition"
        ],
        [
          "Central Minus"
        ],
        [
          "Quantity limited request - Records"
        ],
        [
          "Detectors"
        ],
        [
          "Feeling relief"
        ],
        [
          "Weighing patient"
        ],
        [
          "Make - Instruction Imperative"
        ],
        [
          "Menopause"
        ],
        [
          "Electrocardiogram"
        ],
        [
          "Friendly"
        ],
        [
          "Abnormally low (qualifier value)"
        ],
        [
          "Intervention regimes"
        ],
        [
          "T prime"
        ],
        [
          "Sports"
        ],
        [
          "Internet"
        ],
        [
          "Symptomatic congestive heart failure"
        ],
        [
          "Falls"
        ],
        [
          "Adapt (substance)"
        ],
        [
          "spring (season)"
        ],
        [
          "Prosthesis"
        ],
        [
          "Rating (action)"
        ],
        [
          "Consistency"
        ],
        [
          "DELIVER (Dietary Supplement)"
        ],
        [
          "user - individual"
        ],
        [
          "User Interface Device Component"
        ],
        [
          "Display - arrangement"
        ],
        [
          "Fetus"
        ],
        [
          "Deterioration"
        ],
        [
          "Molecular oxygen saturation"
        ],
        [
          "Analog"
        ],
        [
          "Surveys"
        ],
        [
          "Weekly"
        ],
        [
          "Temperature Sensor Device Component"
        ],
        [
          "Sensor Device Component"
        ],
        [
          "Uniform - quality"
        ],
        [
          "Automated (qualifier value)"
        ],
        [
          "Sleep Apnea, Obstructive"
        ],
        [
          "electrode"
        ],
        [
          "Uterine Contraction"
        ],
        [
          "Elderly fall"
        ],
        [
          "Numerical value"
        ],
        [
          "Entire upper arm"
        ]
      ],
      "id": "52f895602059c6d71c000040",
      "ideal_answer": "As both genesis and symptoms of heart failure exacerbation are non-uniform and complex, the telemonitoring concepts for heart failure patients should employ continuous monitoring of multiple diagnostic parameters, rather than rely on a single parameter. Patients in the intervention arm transmitted weekly blood pressure readings wirelessly, using adapted sensors via mobile phones to a central server. this terminal is very helpful in special circumstances such as disaster relief, dangerous outdoor sports and adventure monitoring, and antiterrorism activities. We describe a vital sign telemonitor (VST) that acquires, records, displays, and provides readings such as: electrocardiograms (ECGs), temperature (T), and oxygen saturation (SaO2) over the Internet to any site. The design of this system consisted of three parts: sensors, analog signal processing circuits, and a user-friendly graphical user interface (GUI). VTAM (Vetement de Tele-Assistance Medicale) presents a T-shirt made from textile with woven wires and incorporating four smooth dry ECG electrodes, a breath rate sensor, a shock/fall detector and two temperature sensors. Body weight, patient activity, and the difference between MHR and RHR are mutually correlated and may reasonably contribute to an algorithm for predicting heart failure deterioration. "
    },
    {
      "exact_answer": "yes",
      "id": "52f896ae2059c6d71c000045",
      "ideal_answer": "The OPIDN after both acute and low-level prolonged exposures develops peripheral neuropathy. The selective involvement of the large diameter sensory fibres (250 Hz and 2000 Hz) were reflective of toxic peripheral neuropathy. A cross sectional study was conducted to investigate the effect of pesticide exposure on the activity of serum cholinesterase (ChE) and current perception threshold (CPT). The results were suggestive of subclinical impairment of distal axonopathy considering the fact only 25% of the farmer showed clinical manifestation of numbness. Saku disease, an optico-autonomic peripheral neuropathy, has been described in Japan in people living in an area where organophosphates were used. "
    },
    {
      "exact_answer": [
        [
          "DCX gene"
        ],
        [
          "Integer +2"
        ],
        [
          "SUBCORTICAL BAND HETEROTOPIA, X-LINKED"
        ],
        [
          "Periodic"
        ],
        [
          "de novo"
        ]
      ],
      "id": "52f899952059c6d71c00004b",
      "ideal_answer": "We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel \"de novo\" missense substitution, Met1Val (M1V), was identified in the DCX gene. "
    },
    {
      "exact_answer": "yes",
      "id": "52f89ee42059c6d71c00004d",
      "ideal_answer": "Here we demonstrate that VPA is a novel activator of AMP-activated protein kinase (AMPK), a key regulator of cellular metabolism, using primary mouse and human hepatocytes. These studies are the first to establish VPA and its metabolites as in vitro activators of AMPK. "
    },
    {
      "exact_answer": [
        [
          "National Cancer Institute"
        ],
        [
          "Negation"
        ],
        [
          "CYR61 gene"
        ],
        [
          "RNA, Messenger"
        ],
        [
          "Cultured Cell Line"
        ]
      ],
      "id": "52f89fc62059c6d71c000050",
      "ideal_answer": "BHLHB3 gene overexpression inhibited colony formation of A549, NCI-H520 and NCI-H596 lung cancer cells. Functional studies in A549 bronchioalveolar carcinoma and NCI-H520 squamous cell carcinoma cells revealed that Msi1 was enriched in spheroid cultures of tumor cells and in the CD133+ cell population. In 4 lung cancer cell strains, BNIP3L protein was not detected in A549, NCI-H460, NCI-H446, except for NCI-H520, in which the protein expression level was slightly lower than that in immortal bronchial epithelial cell strain HBE4-E6/E7. We show that CLN3 mRNA and protein are overexpressed in glioblastoma (U-373G and T98g), neuroblastoma (IMR-32 and SK-N-MC), prostate (Du145, PC-3, and LNCaP), ovarian (SK-OV-3, SW626, and PA-1), breast (BT-20, BT-549, and BT-474), and colon (SW1116, SW480, and HCT 116) cancer cell lines but not in pancreatic (CAPAN and As-PC-1) or lung (A-549 and NCI-H520) cancer cell lines. Importantly, the non-small cell lung carcinoma cell lines expressed either liver-specific (non-neuronal) mRNA (cell line A549) or predominantly the neuronal (cell line NCI-H520) AADC message. "
    },
    {
      "exact_answer": [
        [
          "GATA1 protein, human"
        ],
        [
          "GATA1 gene"
        ],
        [
          "Zinc Finger Protein ZFPM1"
        ],
        [
          "Erythroid"
        ],
        [
          "complex (molecular entity)"
        ],
        [
          "GFI1 gene"
        ],
        [
          "Proteins"
        ],
        [
          "Erythropoiesis"
        ],
        [
          "LDB1 gene"
        ],
        [
          "Fog"
        ],
        [
          "Essential"
        ],
        [
          "Interaction"
        ],
        [
          "Partner in relationship"
        ],
        [
          "PIAS3 protein, human"
        ],
        [
          "LRSAM1 gene"
        ],
        [
          "1B"
        ],
        [
          "Manufactured ski"
        ],
        [
          "Lanugo (invertebrate)"
        ],
        [
          "QRSL1 gene"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "Biotinylation"
        ],
        [
          "SPI1 wt Allele"
        ],
        [
          "Binding (Molecular Function)"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ],
        [
          "LIM Domain Protein"
        ],
        [
          "Histopathologic Grade differentiation"
        ],
        [
          "Transcriptional Repression"
        ],
        [
          "Mediator of activation protein"
        ],
        [
          "Providing (action)"
        ],
        [
          "Hematopoietic factor"
        ],
        [
          "Hematopoietic"
        ],
        [
          "Biologic Development"
        ],
        [
          "Endogenous"
        ],
        [
          "Expression procedure"
        ],
        [
          "Early Growth Response Protein 1"
        ],
        [
          "Numbers"
        ],
        [
          "Function"
        ],
        [
          "Mutant"
        ],
        [
          "TRANSCRIPTION FACTOR"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Evidence of"
        ],
        [
          "Factor"
        ],
        [
          "CNTN2 gene"
        ],
        [
          "LMO4 gene"
        ],
        [
          "NR1I2 gene"
        ],
        [
          "EP300 wt Allele"
        ],
        [
          "HNF1A gene"
        ],
        [
          "TAL1 gene"
        ],
        [
          "Wegener Granulomatosis"
        ],
        [
          "Acute Erythroblastic Leukemia"
        ],
        [
          "CDK9 gene"
        ],
        [
          "EGR1 gene"
        ],
        [
          "Genes, vif"
        ],
        [
          "EIF4E wt Allele"
        ],
        [
          "literary novel"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Megakaryocytic maturation"
        ],
        [
          "Traverse"
        ],
        [
          "LIM domain binding"
        ],
        [
          "Mus"
        ],
        [
          "Central Minus"
        ],
        [
          "K562 Cells"
        ],
        [
          "Adoptive Immunotherapy"
        ],
        [
          "Does pull"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Zinc Fingers"
        ],
        [
          "Oncogenes"
        ],
        [
          "Erythroid Cells"
        ],
        [
          "Proteomics"
        ],
        [
          "Skin tag"
        ],
        [
          "Overlap"
        ],
        [
          "Explanation"
        ],
        [
          "Lymphoid"
        ],
        [
          "Myeloid"
        ],
        [
          "chromatin location"
        ],
        [
          "Chromatin"
        ],
        [
          "Mediate"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Percent normal"
        ],
        [
          "Metabolic Suppression"
        ],
        [
          "Block (unit of measure)"
        ],
        [
          "% deficient"
        ],
        [
          "Example"
        ],
        [
          "Characterization"
        ],
        [
          "Numerous"
        ],
        [
          "Program"
        ],
        [
          "Late"
        ],
        [
          "Involvement with"
        ],
        [
          "point - UnitsOfMeasure"
        ],
        [
          "Cell Proliferation"
        ],
        [
          "transcription factor binding"
        ],
        [
          "transcription factor complex"
        ],
        [
          "Occur (action)"
        ],
        [
          "Additional"
        ],
        [
          "Confirmed by"
        ],
        [
          "Application procedure"
        ],
        [
          "Binding action"
        ],
        [
          "Critical"
        ],
        [
          "Stage"
        ],
        [
          "Direct type of relationship"
        ]
      ],
      "id": "52f89fd32059c6d71c000051",
      "ideal_answer": "We next applied the biotinylation tag to Ldb-1, a known partner of GATA-1, and characterized a number of novel interaction partners that are essential in erythroid development, in particular, Eto-2, Lmo4, and CdK9. We also provide evidence that distinct GATA-1 complexes are associated with specific GATA-1 functions in erythroid differentiation, for example, GATA-1/Gfi-1b with the suppression of cell proliferation and GATA-1/FOG-1/MeCP1 with the repression of other hematopoietic transcription programs. Our work describes, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes. Using a biotinylation tagging/proteomics approach in erythroid cells, we describe distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes. Importantly, we show that FOG-1 mediates GATA-1 interactions with the MeCP1 complex, thus providing an explanation for the overlapping functions of these two factors in erythropoiesis. Endogenous GATA1 and LDB1 proteins were confirmed to bind to LMO2-C by MBP pull down analysis. "
    },
    {
      "exact_answer": [
        [
          "SLC16A2 gene"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Mutation"
        ],
        [
          "Membrane Transport Proteins"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ]
      ],
      "id": "52f8b2902059c6d71c000053",
      "ideal_answer": "One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects. One, producing severe psychomotor defects in \u003e 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;. Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TRβ, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases. AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport. "
    },
    {
      "exact_answer": [
        [
          "Transcription Repressor/Corepressor"
        ],
        [
          "HMOX1 gene"
        ],
        [
          "TRANSCRIPTION FACTOR"
        ],
        [
          "Heme"
        ],
        [
          "Heme Oxygenase-1"
        ]
      ],
      "id": "52fa6ac72059c6d71c000055",
      "ideal_answer": "its regulatory mechanism by the transcriptional repressor, BTB and CNC homology 1 (Bach1),. Bach1, the negative regulator of Nrf2. Here we show that the transcription factor Bach1 (BTB and CNC homology 1, basic leucine zipper transcription factor 1), which inhibits oxidative stress-inducible genes, is a crucial negative regulator of oxidative stress-induced cellular senescence. evidence that BACH1 acts as a transcriptional repressor in the regulation of MARE-dependent genes. transcription factor Bach1 functions as a repressor of the enhancers of heme oxygenase-1 (HO-1) gene (Hmox-1). transcription factor Bach1 heterodimerizes with small Maf proteins to repress Maf recognition element (MARE)-dependent gene expression. The mechanism underlying Bach1-mediated HO-1 repression is less well understood. Bach1 forms a heterodimer with small Maf family, and functions as a repressor of the Maf recognition element (MARE) in vivo. Transcription factor BACH1 [BTB (broad-complex, tramtrack and bric-a-brac) and CNC (cap\u0027n\u0027collar protein) homology 1] binds to ARE-like sequences, functioning as a transcriptional repressor. The inhibitory role for Bach1 may stem from its activity to repress gene expression including HO-1. a heme-binding factor, Bach1, is a critical physiological repressor of ho-1. Bach1 is a repressor of the oxidative stress response. the transcriptional repressor BACH1 binds ARE-like enhancers. "
    },
    {
      "exact_answer": [
        [
          "Corrected QT Interval"
        ],
        [
          "Ms. - Title"
        ],
        [
          "Short Qt Syndrome"
        ],
        [
          "Entity"
        ],
        [
          "Syncope"
        ]
      ],
      "id": "52fb7c512059c6d71c000069",
      "ideal_answer": "Short QT syndrome is a newly described cardiologic entity which associates a short OT interval (QT and QTc \u003c or \u003d 300 ms) on the surface ECG to a high risk of syncope or sudden death due to malignant ventricular arrhythmia. The short-QT syndrome is a new clinical entity characterized by corrected QT intervals \u003c300 ms and a high incidence of ventricular tachycardia (VT) and fibrillation (VF). The short QT syndrome constitutes a new clinical entity that is associated with a high incidence of sudden cardiac death, syncope, and/or atrial fibrillation even in young patients and newborns. In children with QTc below 330 ms (2nd degree of shortening) short QT syndrome should be excluded. Patients with this congenital electrical abnormality are characterized by rate-corrected QT intervals\u003c320 ms. QT interval is shortened when QTc is less than 350 ms (1st degree of shortening). "
    },
    {
      "exact_answer": "yes",
      "id": "52fc946d2059c6d71c000071",
      "ideal_answer": "Merck\u0027s lambrolizumab (MK-3475) monoclonal antibody received \"Breakthrough Therapy\" designation from the U.S. Food and Drug Administration in April for treating patients with advanced melanoma. The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. "
    },
    {
      "id": "52fc94ae2059c6d71c000073",
      "ideal_answer": "Passive immunotherapy with monoclonal antibodies (mAbs) against Aβ is in late clinical development but recently the two most advanced mAbs, Bapineuzumab and Solanezumab, targeting an N-terminal or central epitope, respectively. Solanezumab is a humanized anti-amyloid β monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). This situation was encountered in the development of LY2062430, a therapeutic mid-domain monoclonal anti-amyloid beta peptide (Aβ) antibody undergoing clinical trials for the treatment of Alzheimer\u0027s disease. LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD. Anti-amyloid treatment in asymptomatic AD (A4) is a prevention trial aimed at treating older individuals with normal cognition but at risk of developing AD dementia on the basis of having biomarker evidence of amyloid (preclinical AD). Immunotherapeutic agents have been developed to remove the neurotoxic amyloid β42 protein and prevent the hypothesized amyloid β42-induced neurotoxicity and neurodegeneration. Clinical trials on various drugs, including AN1792, bapineuzumab, and solanezumab,. Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of β-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer\u0027s disease (AD). "
    },
    {
      "exact_answer": [
        [
          "bapineuzumab"
        ],
        [
          "solanezumab"
        ],
        [
          "Blood group antibody A"
        ],
        [
          "Antibodies, Monoclonal, Humanized"
        ],
        [
          "Monoclonal Antibodies"
        ],
        [
          "Meningoencephalitis"
        ],
        [
          "APP protein, human"
        ],
        [
          "Staphylococcal Protein A"
        ],
        [
          "Octagam"
        ],
        [
          "Phase 3 Clinical Trials"
        ],
        [
          "Patients"
        ],
        [
          "Peptides"
        ],
        [
          "QS 21"
        ],
        [
          "Immunologic Adjuvants"
        ],
        [
          "Clinical Trial [Publication Type]"
        ],
        [
          "ponezumab"
        ],
        [
          "gantenerumab"
        ],
        [
          "Changing"
        ],
        [
          "Abandoned"
        ],
        [
          "SUCLA2 gene"
        ],
        [
          "First (number)"
        ],
        [
          "passive immunization procedure"
        ],
        [
          "immunologic"
        ],
        [
          "Administration occupational activities"
        ],
        [
          "Vaccination"
        ],
        [
          "Administration of vaccine to produce active immunity"
        ],
        [
          "AN-1792"
        ],
        [
          "Polyclonal antibody"
        ],
        [
          "Numerous"
        ],
        [
          "are unit of measure"
        ],
        [
          "Continuous"
        ],
        [
          "Vaccine - EntityCode"
        ],
        [
          "Advanced phase"
        ],
        [
          "Synthesis"
        ],
        [
          "Direct type of relationship"
        ],
        [
          "Phase 2 Clinical Trials"
        ],
        [
          "Failed"
        ],
        [
          "APP wt Allele"
        ],
        [
          "Ability"
        ],
        [
          "Tests (qualifier value)"
        ],
        [
          "Experimental Result"
        ],
        [
          "Vaccinated at"
        ],
        [
          "Epitopes"
        ],
        [
          "Large"
        ],
        [
          "Active"
        ],
        [
          "Aggregation"
        ],
        [
          "Proteins"
        ],
        [
          "Blood group antigen A"
        ],
        [
          "Antibodies"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Disease"
        ],
        [
          "Alzheimer\u0027s Disease Pathway KEGG"
        ],
        [
          "Fulfill"
        ],
        [
          "Type - attribute"
        ],
        [
          "Encephalomyelitis"
        ],
        [
          "Procedural approach"
        ],
        [
          "Abnormally high"
        ],
        [
          "Study Terminated"
        ],
        [
          "Generic Role"
        ],
        [
          "Approximate"
        ],
        [
          "Investigates"
        ],
        [
          "Consistency"
        ],
        [
          "Immunotherapy"
        ],
        [
          "Subgroup"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Conjugated"
        ],
        [
          "Amyloid related imaging abnormalities"
        ],
        [
          "Immunization"
        ],
        [
          "Immunotherapy, Passive"
        ],
        [
          "Passive Method"
        ],
        [
          "Carrier of disorder"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Burden"
        ],
        [
          "pathogenic aspects"
        ],
        [
          "Gender Status - Intact"
        ],
        [
          "Peptide Fragments"
        ],
        [
          "Preliminary results"
        ],
        [
          "Causing"
        ],
        [
          "Fragment of (qualifier value)"
        ],
        [
          "Possibly Related to Intervention"
        ],
        [
          "monoclonal"
        ],
        [
          "Providing (action)"
        ],
        [
          "Preparation"
        ],
        [
          "synthetic peptide"
        ],
        [
          "Cognitive"
        ],
        [
          "strategy"
        ],
        [
          "Involvement with"
        ],
        [
          "Induce (action)"
        ],
        [
          "Disease Progression"
        ],
        [
          "Clinical Trials"
        ],
        [
          "End Point"
        ],
        [
          "Now (temporal qualifier)"
        ],
        [
          "Course"
        ],
        [
          "Efficacy Study"
        ],
        [
          "Activities"
        ],
        [
          "Does play"
        ],
        [
          "incidence of cases"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Evaluation procedure"
        ],
        [
          "Patient performance"
        ]
      ],
      "id": "52fc94db2059c6d71c000074",
      "ideal_answer": "Unfortunately, the first active vaccine (AN1792, consisting of preaggregate Aβ and an immune adjuvant, QS-21) was abandoned because it caused meningoencephalitis in approximately 6% of treated patients. An active anti-Aβ vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned. The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-Aβ immunization is able to alter the course if this devastating disease. The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-Aβ immunization is able to alter the course of this devastating disease. Several types of Aβ peptide immunotherapy for Alzheimer\u0027s disease are under investigation, direct immunization with synthetic intact Aβ(42) , active immunization involving the administration of synthetic fragments of Aβ peptide conjugated to a carrier protein and passive administration with monoclonal antibodies directed against Aβ peptide. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce Aβ burden in the brain of AD patients. "
    },
    {
      "exact_answer": "yes",
      "id": "530cefaaad0bf1360c000004",
      "ideal_answer": "Bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer\u0027s disease. Despite negative topline phase 3 clinical trial results for bapineuzumab and solanezumab in mild to moderate AD, findings from these trials and recent advances suggest renewed optimism for anti-amyloid therapies. Clinical studies using the N-terminal-directed anti-Aβ antibody bapineuzumab have demonstrated reduced brain PET-Pittsburg-B signals, suggesting the reduction of Aβ plaques, and reduced levels of total and phosphorylated tau protein in the CSF of treated AD patients. Passive immunotherapy with monoclonal antibodies (mAbs) against Aβ is in late clinical development but recently the two most advanced mAbs, Bapineuzumab and Solanezumab, targeting an N-terminal or central epitope, respectively, failed to meet their target of improving or stabilizing cognition and function. The marginal effects observed in recent clinical studies of solanezumab, targeting monomeric Aβ, and bapineuzumab, targeting amyloid plaques, prompted expert comments that drug discovery efforts in Alzheimer\u0027s disease should focus on soluble forms of Aβ rather than fibrillar Aβ deposits found in amyloid plaques. "
    },
    {
      "exact_answer": "yes",
      "id": "530cefaaad0bf1360c000005",
      "ideal_answer": "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding. For recurrent acute venous thromboembolism, there were no significant differences in events rates between any of the anticoagulants and conventional treatment (rivaroxaban (four studies): relative risk 0.85, 95% confidence interval 0.55 to 1.31; dabigatran (two studies): 1.09, 0.76 to 1.57; ximelagatran (two studies): 1.06, 0.62 to 1.80; and apixaban (one study): 0.98, 0.20 to 4.79). Rivaroxaban reduced the risk of major bleeding compared with conventional treatment (0.57, 0.39 to 0.84), whereas other novel oral anticoagulants did not (0.76 (0.49 to 1.18) for dabigatran; 0.54 (0.28 to 1.03) for ximelagatran; 2.95 (0.12 to 71.82) for apixaban). Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. For all cause mortality there were no significant differences between the novel oral anticoagulants and conventional treatment (0.96 (0.72 to 1.27) for rivaroxaban; 1.00 (0.67 to 1.50) for dabigatran; 0.67 (0.42 to 1.08) for ximelagatran; 6.89 (0.36 to 132.06) for apixaban). "
    },
    {
      "exact_answer": "yes",
      "id": "530cefaaad0bf1360c000008",
      "ideal_answer": "Merck\u0027s lambrolizumab (MK-3475) monoclonal antibody received \"Breakthrough Therapy\" designation from the U.S. Food and Drug Administration in April for treating patients with advanced melanoma. However, through parallel efforts that have showcased the efficacy of small-molecule BRAF and MAP-ERK kinase (MEK) inhibitors, as well as the immune checkpoint inhibitors, namely ipilimumab and the anti-PD1/PDL1 antibodies (lambrolizumab, nivolumab, MPDL3280), an opportunity exists to transform the treatment of melanoma specifically and cancer generally by exploring rational combinations of molecularly targeted therapies, immunotherapies, and molecular targeted therapies with immunotherapies. The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. The most mature results have been obtained in advanced melanoma patients. Because of all these reasons PD-1/PD-L1 antibodies are considered \u0027drug of the year\u0027. "
    },
    {
      "exact_answer": "yes",
      "id": "530cf57efe2466f70c000001",
      "ideal_answer": "significant role of frailty as a predictor of depression in a relatively younger old Chinese population. significant relationships between frailty and depressive symptoms and mortality at 1 year. These findings suggest that malnutrition is a major predictor of frailty or the \"failure to thrive\" syndrome in older persons. Depression is a major cause of poor nutritional status in older persons. Depressed mood was associated with increased risk of steep strength decline, in particular in older men with low body weight. Low body weight in combination with depressed mood may be an indicator of frailty or severe disease status that leads to accelerated strength loss and disability. Longitudinally, depressed mood was the only independent predictor of decline in cognition, functional ability, physician-rated health, and mortality;. "
    },
    {
      "exact_answer": "yes",
      "id": "530cf57efe2466f70c000006",
      "ideal_answer": "Overall, vitamin D did not reduce rate of falls (RaR 1.00, 95% CI 0.90 to 1.11; seven trials; 9324 participants) or risk of falling (RR 0.96, 95% CI 0.89 to 1.03; 13 trials; 26,747 participants), but may do so in people with lower vitamin D levels before treatment. However, apart from the beneficial effects of 800 IU/d of vitamin D3 for reduction of falls in the elderly, causality remains yet unproven in randomized controlled trials (RCTs). The rate of falls and the number of fallers was significantly reduced in two studies evaluating the effect of medication on preventing falls; one study (85 participants) compared vitamin D versus placebo in institutionalised women after stroke with low vitamin D levels, and the other study (79 participants) evaluated alendronate versus alphacalcidol in hospitalised people after stroke. Two studies testing vitamin D versus placebo and alendronate versus alphacalcidol found a significant reduction in falls and the number of people falling. .Overall, vitamin D supplementation does not appear to reduce falls but may be effective in people who have lower vitamin D levels before treatment. Beyond fall and fracture prevention, vitamin D may also reduce overall morbidity by multiple mechanisms. "
    },
    {
      "exact_answer": [
        [
          "Osteodystrophy"
        ],
        [
          "Dystrophia unguium"
        ],
        [
          "Mental Retardation"
        ],
        [
          "Collaborator"
        ],
        [
          "Deafness"
        ],
        [
          "Autosomal recessive inheritance"
        ],
        [
          "Seizures"
        ],
        [
          "Epilepsy"
        ],
        [
          "hearing impairment"
        ],
        [
          "etiology unknown"
        ],
        [
          "Availability of"
        ],
        [
          "Search - action"
        ],
        [
          "Persons"
        ],
        [
          "Communication"
        ],
        [
          "Feature"
        ],
        [
          "Main"
        ],
        [
          "Rare Diseases"
        ],
        [
          "Digitorenocerebral Syndrome"
        ],
        [
          "Family"
        ],
        [
          "Identified"
        ],
        [
          "Case Study"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Three"
        ]
      ],
      "id": "530e1c985937551c09000004",
      "ideal_answer": "Through a search of available case studies and communication with collaborators, we identified families that included at least one individual with at least three of the five main features of the DOORS syndrome: deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures. Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome is a rare autosomal recessive disorder of unknown cause. "
    },
    {
      "exact_answer": [
        [
          "SLC16A2 gene"
        ],
        [
          "Triiodothyronine"
        ],
        [
          "Allan-Herndon-Dudley syndrome (AHDS)"
        ],
        [
          "Thyroid Hormones"
        ],
        [
          "Membrane Transport Proteins"
        ]
      ],
      "id": "530f900ee3eabad021000003",
      "ideal_answer": "With the discovery of monocarboxylate transporter 8 (MCT8) as a specific thyroid hormone transporter and the finding that mutations in this transporter lead to a syndrome of severe psychomotor retardation and elevated serum 3,3\u0027,5-tri-iodothyronine levels known as the Allan-Herndon-Dudley syndrome, the interest in this area of research has greatly increased. The clinical importance of TH transporters is dramatically shown in patients with mutations in MCT8, suffering from severe X-linked psychomotor retardation in combination with disturbed TH levels, especially high serum T(3) levels, now referred as Allan-Herndon-Dudley Syndrome (AHDS). Our results show the difficulty of distinguishing AHDS from patients with X-linked intellectual disability solely on the basis of clinical features and biochemical tests, and we advise screening for MCT8 mutations in either young or older patients with severe intellectual disability, axial hypotonia/dystonia, poor head control, spastic paraplegia, and athetoid movements even when they have normal thyroid hormone profiles. Allan-Herndon-Dudley syndrome (AHDS), an X linked condition, is characterized by severe intellectual disability, dysarthria, athetoid movements, muscle hypoplasia and spastic paraplegia in combination with altered TH levels, in particular, high serum T3 levels. "
    },
    {
      "exact_answer": [
        [
          "Serum creatinine level"
        ],
        [
          "Glomerular Filtration Rate"
        ],
        [
          "Vancomycin"
        ],
        [
          "FBXL20 gene"
        ],
        [
          "Blood urea nitrogen measurement"
        ],
        [
          "Proteinuria"
        ],
        [
          "Withholding Treatment"
        ],
        [
          "Cystatin C (substance)"
        ],
        [
          "Nephrotoxic"
        ],
        [
          "pioglitazone"
        ],
        [
          "Renal function"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Tryptophan"
        ],
        [
          "Glomerular filtration rate finding"
        ],
        [
          "Increase"
        ],
        [
          "Kynurenic Acid"
        ],
        [
          "Kynurenine"
        ],
        [
          "month"
        ],
        [
          "Estimated"
        ],
        [
          "Chronic Kidney Diseases"
        ],
        [
          "Measured"
        ],
        [
          "Associated with"
        ],
        [
          "Risk"
        ],
        [
          "EAF2 gene"
        ],
        [
          "Preposition For"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Negation"
        ],
        [
          "Kidney"
        ],
        [
          "Biological Markers"
        ],
        [
          "Informing patient"
        ],
        [
          "Societies"
        ],
        [
          "Tumor Grading System"
        ],
        [
          "Encounter due to being a donor"
        ],
        [
          "Encounter due to kidney donor status"
        ],
        [
          "Interested"
        ],
        [
          "Diabetic Nephropathy"
        ],
        [
          "Replace"
        ],
        [
          "Decreased glomerular filtration rate"
        ],
        [
          "Dog family"
        ],
        [
          "Blood urea increased"
        ],
        [
          "Weekly"
        ],
        [
          "Return to"
        ],
        [
          "Definition"
        ],
        [
          "Critically ill children"
        ],
        [
          "Largest"
        ],
        [
          "Living Donors"
        ],
        [
          "Reversible"
        ],
        [
          "Administration of medication"
        ],
        [
          "Locus"
        ],
        [
          "Implementation"
        ],
        [
          "Gender"
        ],
        [
          "Changed status"
        ],
        [
          "Entire kidney"
        ],
        [
          "International"
        ],
        [
          "Percent normal"
        ],
        [
          "Removal of kidney from donor"
        ],
        [
          "Urine"
        ],
        [
          "Dietary Lead"
        ],
        [
          "Complication"
        ],
        [
          "Failed"
        ],
        [
          "Serious"
        ],
        [
          "Mental concentration"
        ],
        [
          "Mental association"
        ],
        [
          "Urinary tract"
        ],
        [
          "Abnormal renal function"
        ],
        [
          "Relationships"
        ],
        [
          "per month (qualifier value)"
        ],
        [
          "Continuous"
        ],
        [
          "Kidney Diseases"
        ],
        [
          "Acute kidney injury"
        ],
        [
          "Determination Aspects"
        ],
        [
          "Kidney Failure"
        ],
        [
          "development aspects"
        ],
        [
          "Animals, Laboratory"
        ],
        [
          "Correlation"
        ],
        [
          "Status"
        ],
        [
          "Ratio"
        ],
        [
          "Post"
        ],
        [
          "Reduction - action"
        ],
        [
          "Evaluation"
        ],
        [
          "Detection"
        ],
        [
          "Decrease"
        ],
        [
          "drug management"
        ],
        [
          "Life"
        ],
        [
          "acute"
        ],
        [
          "Decreased"
        ],
        [
          "Diagnosis"
        ],
        [
          "Small"
        ],
        [
          "Age"
        ],
        [
          "In Blood"
        ],
        [
          "Observed"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Use studies"
        ],
        [
          "Long-term"
        ],
        [
          "{Non-patient}"
        ]
      ],
      "id": "5311b99ae3eabad021000004",
      "ideal_answer": "In living kidney donors GFR is not significantly correlated with age or sex. Serum creatinine, blood urea nitrogen, cystatin C, and estimated GFR (eGFR), based on serum creatinine have failed to replace mGFR. After kidney donation, renal function measured by blood urea nitrogen (BUN) and serum creatinine of all donors returned to normal within one week, and no serious complications were noticed. kidney dysfunction and decreased glomerular filtration rate (GFR) are diagnosed by the evaluation of changes in the serum creatinine (SCr) and blood urea nitrogen (BUN) concentrations. In critically ill children, the development of reversible AKI during vancomycin therapy is associated with administration of nephrotoxic drugs and an elevated BUN: Scr ratio. A reduction of proteinuria in patients with non-diabetic renal disease was observed during the 4-month treatment with pioglitazone which continued for 2 months after the cessation of the treatment. Decreased tryptophan (TRP) and increased kynurenine (KYN) and kynurenic acid (KYNA) in blood have been reported in patients and experimental animals with renal diseases. However, 4 months after the cessation of the treatment, a little increase was detected in the level of proteinuria. Increased proteinuria would lead to a larger risk for renal failure in the long term. "
    },
    {
      "exact_answer": "yes",
      "id": "5311ceeae3eabad021000008",
      "ideal_answer": "And the protein expression of Egr-1 was detected by using western blot and immunohistochemistry analyses. Early growth response gene-1 (Egr-1) mRNA was measured using reverse transcription-PCR and in situ hybridization. However, analysis of Lhx2 function at later stages of cortical development has been hampered by severe phenotypes associated with early loss of function. The LIM homeobox gene Lhx2 is expressed in cortical progenitors during development and also in the superficial layers of the neocortex in maturity. The vein graft samples were obtained on each time point after surgery. The expression of the EDRz transfected in the vein graft was detected using a fluorescent microscope. Tissue Transglutaminase (TG2) is a multifunctional enzyme, which amongst other functions, is involved in cell differentiation. Therefore, we hypothesized that TG2 contributes to differentiation of OPCs into OLGs and thereby stimulates remyelination. "
    },
    {
      "exact_answer": "yes",
      "id": "5314896adae131f847000001",
      "ideal_answer": "The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. Mowat-Wilson syndrome (MWS; OMIM #235730) is a genetic condition caused by heterozygous mutations or deletions of the ZEB2 gene, and characterized by typical face, moderate-to-severe mental retardation, epilepsy, Hirschsprung disease, and multiple congenital anomalies, including genital anomalies (particularly hypospadias in males), congenital heart defects, agenesis of the corpus callosum, and eye defects. Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly syndrome characterized by a distinct facial phenotype (high forehead, frontal bossing, large eyebrows, medially flaring and sparse in the middle part, hypertelorism, deep set but large eyes, large and uplifted ear lobes, with a central depression, saddle nose with prominent rounded nasal tip, prominent columella, open mouth, with M-shaped upper lip, frequent smiling, and a prominent but narrow and triangular pointed chin), moderate-to-severe intellectual deficiency, epilepsy and variable congenital malformations including Hirschsprung disease (HSCR), genitourinary anomalies (in particular hypospadias in males), congenital heart defects, agenesis of the corpus callosum and eye anomalies. "
    },
    {
      "id": "5314ad66dae131f847000004",
      "ideal_answer": "Still with regard to antibiotic treatment in women, a recently published study investigated also the potential cranberry juice interaction with beta-lactam antibiotics supporting the hypothesis that cranberry juice in usual quantities as prophylaxis for UTI is not likely to alter the pharmacokinetics of these oral antibiotics. Cranberry juice has long been recognized in folk medicine as a therapeutic agent, mainly in urinary tract infections. Inhibition of adherence to an extent of about 70% with multi-drug resistant E. coli strains was observed on uroepithelial cell. In vitro studies have shown that binding of the P fimbriae of Escherichia coli to the uroepithelial tissue can be inhibited in the presence of proanthocyanidins, the active ingredient of cranberries. The anti-adherence bioactivity of the proanthocyanidin was detected at concentrations of 10-50 µg/ml with significant bacteriuria. NDM at concentrations between 0.2/mL and 1mg/mL significantly (P\u003c.05) decreased secretion of extracellular FTF, as well as down-regulated ftf expression in a dose-dependent manner. The AFM adhesion force measurements were consistent with the results of a hemagglutination assay, confirming that oral consumption of CJC could act against adhesion of uropathogenic E. coli. "
    },
    {
      "exact_answer": "yes",
      "id": "5316111fb166e2b806000001",
      "ideal_answer": "Statin-mediated upregulation of klotho expression and differential regulation of FoxO expression promote resistance to CsA-induced oxidative stress. This differentiation process is associated with the induction of the forkhead transcription factor FOXO1, which in turn increases the expression of the mitochondrial antioxidant manganese superoxide dismutase. These results suggest that the induction of FOXO1 may enhance the ability of decidualized cells to prevent oxidative damage while the simultaneous repression of FOXO3a expression disables the signaling pathway responsible for oxidative cell death. Comparative analysis demonstrated that hydrogen peroxide, a source of free radicals, strongly induces FOXO3a mRNA and protein expression in undifferentiated human endometrial stromal cells but not in decidualized cells. We demonstrate that human endometrial stromal cells become extraordinarily resistant to oxidative stress-induced apoptosis upon decidualization in response to cAMP and progesterone signaling. Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. The differential regulation of FOXO expression provides the decidua with a robust system capable of coping with prolonged episodes of oxidative stress during pregnancy. Forkhead-box class O (FoxO) transcription factors regulate mechanisms of cellular aging, including protein quality control, autophagy and defenses against oxidative stress. "
    },
    {
      "exact_answer": [
        [
          "Mismatch Repair"
        ],
        [
          "Hereditary Nonpolyposis Colorectal Cancer"
        ],
        [
          "TGFBR2 protein, human"
        ],
        [
          "Staphylococcal Protein A"
        ],
        [
          "Short Tandem Repeat"
        ]
      ],
      "id": "53161545b166e2b806000002",
      "ideal_answer": "Mutations in the genes of the mismatch DNA repair system and of the TGF-beta-II-receptor, the main defects of the HNPCC (hereditary nonpolyposis colorectal cancer), are exclusively identified in sequences of microsatellites. In HNPCC families, germline mutations in any of four genes encoding proteins of a specialized DNA repair system, the mismatch repair, predispose to cancer development. MMR (mismatch repair)\u0027s genes are involved in carcinogenesis as they play a role in ADNA mismatch repair. The HNPCC syndrome (hereditary non polyposis colon cancer) or Lynch syndrome stands for an autosomic dominant condition leading to the most prevalent hereditary colo-rectal cancers (CCR). "
    },
    {
      "exact_answer": "yes",
      "id": "531616bdb166e2b806000003",
      "ideal_answer": "The current study encompasses the investigation of simultaneous expression of four circadian clock genes (Bmal1, Clock, Per1 and Per2) and three clock-controlled cell cycle genes (Myc, Cyclin D1 and Wee1). We also show that BMAL1 epigenetic inactivation impairs the characteristic circadian clock expression pattern of genes such as C-MYC, catalase, and p300 in association with a loss of BMAL1 occupancy in their respective promoters. Our results suggest that aberrant expression of circadian clock genes can lead to aberrant expression of their downstream targets that are involved in cell proliferation and apoptosis and hence may result in manifestation of CLL. The results showed that over-expression of Per2 induced not only cell cycle arrest at G2/M phase but also an increase in apoptosis, which was confirmed by characteristic morphological changes, FCM and evident DNA fragmentation. Among the circadian output pathways, the rhythmic sympathetic signaling plays a key role in the central-peripheral timing mechanism that simultaneously activates the cell cycle clock via AP1-controlled Myc induction and p53 via peripheral clock-controlled ATM activation. Temporal expression of genes involved in cell cycle regulation and tumor suppression, such as c-Myc, Cyclin D1, Cyclin A, Mdm-2 and Gadd45alpha is deregulated in mPer2 mutant mice. "
    },
    {
      "exact_answer": "yes",
      "id": "5316d4fcb166e2b806000005",
      "ideal_answer": "The pathogenesis of MM involves the accumulation of extensive cytogenetic changes, as well as cancer-related phenotypic alterations that facilitate tumor cell survival, invasion and metastasis. This review presents current knowledge regarding the biological characteristics of this disease that are linked to the so-called hallmarks of cancer. "
    },
    {
      "id": "53173fc5b166e2b806000006",
      "ideal_answer": "causes Timothy syndrome, a neurodevelopmental disorder associated with autism spectrum disorders (ASDs). Timothy syndrome (TS) is an autosomal dominant condition with the constellation of features including prolonged QT interval, hand and foot abnormalities, and mental retardation or autism. Timothy syndrome (TS) is a disease of excessive cellular Ca(2+) entry and life-threatening arrhythmias caused by a mutation in the primary cardiac L-type Ca(2+) channel (Ca(V)1.2). Here, we discuss recent work on the mechanisms by which Ca(v)1.2 channels bearing TS mutations display slowed inactivation that leads to increased Ca(2+) influx, prolonging the cardiac AP and promoting lethal arrhythmias. A gain-of-function G406R mutation in a cytoplasmic loop of Ca(V)1.2 channels causes long QT syndrome 8 (LQT8), a disease also known as Timothy syndrome. Hand/foot findings are unilateral or bilateral cutaneous syndactyly variably involving fingers two (index), three (middle), four (ring), and five (little) and bilateral cutaneous syndactyly of toes two and three. In some rare cases, such as Timothy syndrome (TS), a specific mutation in a single gene can be sufficient to generate autism or ASD in most patients, potentially offering insights into the etiology of autism in general. "
    },
    {
      "exact_answer": "yes",
      "id": "53175e25b166e2b806000007",
      "ideal_answer": "As CHEK2 is a cell-cycle master controller, we tested the hypothesis that heterozygosity for the frameshift alteration CHEK2*1100delC is associated with increased risk of malignant melanoma. CHEK2 is a key cell cycle control gene encoding a pluripotent kinase that can cause arrest or apoptosis in response to unrepaired DNA damage. In the current study, we evaluated the possible associations of seven common variants of the DNA repair and cell cycle control genes BRCA2 and CHEK2 with malignant melanoma (MM). Promotor methylation analysis of key regulatory genes involved in cell cycle control (p14, p15, p16, CHK2), DNA repair (hMLH1), apoptosis (p73, survivin, DAPK), and differentiation (RARb, WT1) was performed by methylation-specific polymerase chain reaction. In response to DNA damage, Chk2 is initially phosphorylated at Thr-68, which leads to its full activation. growth arrest and DNA-damage-inducible, gamma ( GADD45G ) family and serine/threonine-protein kinase Chk2 ( CHEK2)] were also increased. E2F transcription factor (E2F) family and histone deacetylase ( HDAC )] and DNA-repair genes [i.e. Moreover, cell-cycle progression genes [i.e. High-fidelity maintenance of genomic integrity in eukaryotes is ensured by cell cycle checkpoints and DNA repair. Checkpoint kinase 2 (hCHK2/hCds1) is a tumor suppressor gene involved in cell-cycle control. "
    },
    {
      "id": "53175e4fb166e2b806000008",
      "ideal_answer": "The Period (Per) genes are key circadian rhythm regulators in mammals. Period (Per) genes are key circadian rhythm regulators in mammals. Temporal expression of genes involved in cell cycle regulation and tumor suppression, such as c-Myc, Cyclin D1, Cyclin A, Mdm-2 and Gadd45alpha is deregulated in mPer2 mutant mice. The temporal expression of genes involved in cell cycle regulation and tumor suppression, such as c-Myc, Cyclin D1, Cyclin A, Mdm-2, and Gadd45alpha, is deregulated in mPer2 mutant mice. Expression of the mouse Per (mPer) genes have diurnal pattern in the suprachiamstic nuclei and in peripheral tissues. Expression of mouse Per (mPer) genes has a diurnal pattern in the suprachiasmatic nucleus and in peripheral tissues. Genetic ablation mPER1 and mPER2 function results in a complete loss of circadian rhythm control based on wheel running activity in mice. Genetic ablation mPER1 and mPER2 function results in a complete loss of circadian rhythm control based on wheel-running activity in mice. In addition, these animals also display apparent premature aging and significant increase in neoplastic and hyperplastic phenotypes. In addition, these animals also display apparent premature aging and a significant increase in neoplastic and hyperplastic phenotypes. "
    },
    {
      "id": "53175e68b166e2b806000009",
      "ideal_answer": "The sulforaphane-induced mitotic arrest correlated with an induction of cyclin B1 and phosphorylation of Cdk1, as well as a concomitant increased complex between cyclin B1 and Cdk1. Taken together, these findings suggest that emodin mediated oxidative injury (DNA damage) based on ROS production and ER stress based on the levels of GADD153 and GRP78 that acts as an early and upstream change in the cell death cascade to caspase- and mitochondria-dependent signaling pathways, triggers mitochondrial dysfunction from Bcl-2 and Bax modulation, mitochondrial cytochrome c release and caspase activation, consequently leading to apoptosis in SCC-4 cells. Further mechanistic studies revealed that induction of apoptosis is associated with cell cycle arrest at G2/M phase, increased generation of reactive oxygen species (ROS), reduced mitochondrial membrane potential (MMP), release of cytochrome c (Cyto c) and apoptosis inducing factor (AIF) from mitochondria to cytosol, upregulation of Bax, p21 and p53, and down-regulation of Bcl-2, cyclin B1 and cyclin-dependent kinase 1 (CDK1). "
    },
    {
      "exact_answer": [
        [
          "Serine/Threonine Protein Kinase 11"
        ],
        [
          "polyps"
        ],
        [
          "beta catenin"
        ],
        [
          "Haploinsufficiency"
        ],
        [
          "Mucous Membrane"
        ]
      ],
      "id": "53175e9fb166e2b80600000a",
      "ideal_answer": "Recent functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might be responsible for the development of harmatomatous polyps. PJS polyps from all patients showed generalized membrane and cytoplasmic localizations of beta-catenin along the mucosal endothelium. "
    },
    {
      "id": "53175f0bb166e2b80600000c",
      "ideal_answer": "Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. Upon introduction of molecular pathways governing autophagy and necrosis (also called necroptosis or programmed necrosis), we focus on the interconnected character of cell death signals. Intricate cross talk among various programmed cell death pathways including cell death by apoptosis, necroptosis or autophagy plays a critical role in the regulation of PCD. This review article focuses on targeting FLIP (Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein) signaling as a bridge between various PCD processes as an effective approach for cancer management. Necroptosis, a novel form of programmed cell death, is caspase independent but RIPK and RIPK3 dependent. Cell death of 5-fluorouracil (5FU)-treated p53-null GSK3B-silenced colon carcinoma cells occurred via PARP1-dependent and AIF-mediated but RIP1-independent necroptosis. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. In vivo studies showed that drug-resistant xenograft tumor mass was significantly reduced only when 5FU was given after GSK3B inhibition. Inducing programmed cell death (PCD) is a promising method to prevent or inhibit the progression of tumor cells. "
    },
    {
      "exact_answer": "yes",
      "id": "5317606eb166e2b80600000d",
      "ideal_answer": "Induction of tubulin acetylation correlated with inhibition of motility but not proliferation based on a comparison of highly and poorly cytotoxic taxanes (paclitaxel and IDN5390) and tumor cell lines sensitive and resistant to paclitaxel (1A9 and 1A9 PTX22). In this study, we found that paclitaxel induced tubulin acetylation in endothelial and tumor cells, at concentrations that affected cell motility but not proliferation (10(-8) to 10(-9) M, for 4 hours). we found that overexpression of the tubulin deacetylase SIRT2 increased cell motility and reduced cell response to the anti-motility activity of paclitaxel. They also suggest that small molecules that selectively inhibit HDAC6-mediated alpha-tubulin deacetylation, a first example of which is tubacin, might have therapeutic applications as antimetastatic and antiangiogenic agents. Finally, we demonstrated that, similarly to other HDAC6 inhibitors, TPPP/p25 influences the microtubule dynamics by decreasing the growth velocity of the microtubule plus ends and also affects cell motility as demonstrated by time lapse video experiments. Cell motility and adhesion involves dynamic microtubule (MT) acetylation/deacetylation, a process regulated by enzymes as HDAC6, a major cytoplasmic α-tubulin deacetylase. Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility. "
    },
    {
      "exact_answer": "yes",
      "id": "53177803b166e2b80600000e",
      "ideal_answer": "This is the first case of germline mosaicism in tuberous sclerosis proven by molecular genetic analysis and also the first example of female germline mosaicism for a characterized autosomal dominant gene mutation apparently not associated with somatic mosaicism. Mutation screening by RT-PCR and direct sequencing of the TSC2 gene identified a 4 bp insertion TACT following nucleotide 2077 in exon 18 which was present in the three affected children but not in five unaffected siblings or the parents. Absence of the mutation in lymphocyte DNA from the parents was consistent with germline mosaicism and this was confirmed by our finding of identical chromosome 16 haplotypes in affected and unaffected siblings, providing unequivocal evidence of two different cell lines in the gametes. Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Molecular analysis of the TSC2 alleles present in the affected subjects showed that the mutation had been inherited from the mother. There are several case reports of solitary SEGA without any other manifestations of TSC. Usually these cases are thought to be forme fruste of TSC due to somatic mosaicism. This mutation would cause a frameshift and premature termination at codon 703. "
    },
    {
      "exact_answer": [
        [
          "HADH gene"
        ],
        [
          "TP53 wt Allele"
        ],
        [
          "Adrenocortical carcinoma"
        ],
        [
          "Adrenocortical"
        ],
        [
          "Germline Mutation Abnormality"
        ],
        [
          "Malignant neoplasm of adrenal cortex"
        ],
        [
          "Sarcoma - category (morphologic abnormality)"
        ],
        [
          "Family member"
        ],
        [
          "Agreement"
        ],
        [
          "Germ-Line Mutation"
        ],
        [
          "Mutation"
        ],
        [
          "criteria"
        ],
        [
          "Breast"
        ],
        [
          "Family History Domain"
        ],
        [
          "Li-Fraumeni Syndrome"
        ],
        [
          "Family"
        ],
        [
          "Brain"
        ],
        [
          "Cancer Patient"
        ],
        [
          "Age"
        ],
        [
          "High risk of"
        ],
        [
          "Patients"
        ]
      ],
      "id": "531778ddb166e2b80600000f",
      "ideal_answer": "According to the Chompret criteria for LFS, any patient with adrenocortical cancer (ACC), irrespective of age and family history, is at high risk for a TP53 germline mutation. All families with a p53 mutation had at least one family member with a sarcoma, breast, brain, or adrenocortical carcinoma (ACC). "
    },
    {
      "exact_answer": [
        [
          "PARK2 gene"
        ],
        [
          "PARK7 gene"
        ],
        [
          "Autosomal recessive inheritance"
        ],
        [
          "Autosomal Recessive Parkinsonism"
        ],
        [
          "PINK1 gene"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Mutation"
        ],
        [
          "ATP13A2 gene"
        ],
        [
          "Gene Mutation"
        ],
        [
          "Genes"
        ],
        [
          "PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE"
        ],
        [
          "Formation"
        ],
        [
          "Phosphotransferases"
        ],
        [
          "Early-onset"
        ],
        [
          "Genes, vif"
        ],
        [
          "Associated with"
        ],
        [
          "Parkinsonian Disorders"
        ],
        [
          "Parkinsonism, early-onset"
        ],
        [
          "Relate - vinyl resin"
        ],
        [
          "group VI phospholipase A2"
        ],
        [
          "Has focus"
        ],
        [
          "Major"
        ],
        [
          "Three"
        ],
        [
          "Proteins"
        ],
        [
          "Identified"
        ],
        [
          "TNS1 gene"
        ],
        [
          "OSS tumor staging notations"
        ],
        [
          "SNCA gene"
        ],
        [
          "phosphoric monoester hydrolase activity"
        ],
        [
          "Homozygote"
        ],
        [
          "Pink color"
        ],
        [
          "Heterozygote"
        ],
        [
          "PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE (disorder)"
        ],
        [
          "Parkinson Disease 6, Autosomal Recessive Early-Onset"
        ],
        [
          "PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE"
        ],
        [
          "Parkinson Disease"
        ],
        [
          "Park (environment)"
        ],
        [
          "Manufactured form"
        ],
        [
          "Infrequent"
        ],
        [
          "Encode (action)"
        ],
        [
          "Hereditary"
        ],
        [
          "Representation (action)"
        ],
        [
          "Does carry"
        ],
        [
          "Familial form"
        ],
        [
          "Designated"
        ],
        [
          "Chromosomes, Human, Pair 6"
        ],
        [
          "Qualitative form"
        ],
        [
          "chromosome map"
        ],
        [
          "Homologous Gene"
        ],
        [
          "Variant"
        ],
        [
          "Causing"
        ],
        [
          "Compound (substance)"
        ],
        [
          "Germ-Line Mutation"
        ],
        [
          "Induce (action)"
        ],
        [
          "Onset of (contextual qualifier)"
        ],
        [
          "Responsible to"
        ],
        [
          "Leading"
        ],
        [
          "KUFOR-RAKEB SYNDROME"
        ],
        [
          "year"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Function"
        ],
        [
          "Disease"
        ]
      ],
      "id": "5318367cb166e2b806000012",
      "ideal_answer": "Mutations in the Parkin gene (PARK2) are the major cause of autosomal recessive early-onset parkinsonism. Early onset PD (EOPD) is particularly associated with autosomal recessive (AR) mutations, and three genes, PARK2, PARK7 and PINK1, have been found to carry mutations leading to AR disease. In three forms, caused by mutations in parkin (PARK2), PINK1 (PARK6), or DJ-1 (PARK7),. oss-of-function mutations in Parkin, PINK1, DJ-1 and ATP13A2 cause autosomal recessive parkinsonism with early-onset. we focus on PARK7, an autosomal recessive form of early-onset parkinsonism caused by mutations in the DJ-1 gene. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Homozygous or compound heterozygous mutations in the phosphatase and tensin homolog-induced putative kinase 1 (PINK1) gene are causative of autosomal recessive, early onset Parkinson\u0027s disease. Mutations in other genes, including ATP13A2 (PARK9), PLA2G6 (PARK14), and FBX07 (PARK15), cause more rare forms of recessive parkinsonism with very early-onset (\u003c30 years). A gene causing autosomal recessive parkinsonism of juvenile onset has been mapped to chromosome 6 (PARK 2), and the causative gene has been identified and named parkin. mutations in the parkin gene, in DJ-1, PINK1 and ATP13A2 all cause autosomal-recessive parkinsonism of early onset. "
    },
    {
      "exact_answer": [
        [
          "PARK2 gene"
        ],
        [
          "PSMA7 gene"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ],
        [
          "PICK1 gene"
        ],
        [
          "Partner in relationship"
        ],
        [
          "HSP90 Heat-Shock Proteins"
        ],
        [
          "parkin protein"
        ],
        [
          "Subunit"
        ],
        [
          "Identified"
        ],
        [
          "Binding (Molecular Function)"
        ],
        [
          "Proteins"
        ],
        [
          "TUFM gene"
        ],
        [
          "HSPA9 gene"
        ],
        [
          "G-Protein-Coupled Receptors"
        ],
        [
          "HSPD1 gene"
        ],
        [
          "LRPPRC gene"
        ],
        [
          "CDC37 gene"
        ],
        [
          "receptor"
        ],
        [
          "Binding Protein"
        ],
        [
          "Monoubiquitination"
        ],
        [
          "Polyubiquitination"
        ],
        [
          "Paracentesis"
        ],
        [
          "Synonym"
        ],
        [
          "20S core proteasome complex location"
        ],
        [
          "Type - attribute"
        ],
        [
          "Promotion (action)"
        ],
        [
          "Clone Cells"
        ],
        [
          "Yeast Two-Hybrid System Techniques"
        ],
        [
          "Localized"
        ],
        [
          "Finding"
        ],
        [
          "Assay"
        ],
        [
          "Interaction"
        ],
        [
          "Alpha"
        ]
      ],
      "id": "5318380bb166e2b806000013",
      "ideal_answer": "We have identified the 20S proteasomal subunit alpha4 (synonyms: PSMA7, XAPC7, subunit alpha type 7) as a new interacting partner of parkin. In addition to two known binding partners (HSP90, CDC37), 12 proteins were identified using the TAP assay; four of which are mitochondrially localized (GRP75, HSP60, LRPPRC, and TUFM). we cloned parkin-binding protein using a yeast two-hybrid system and identified a putative G protein-coupled receptor protein,which we named the Pael receptor (Pael-R). We find that parkin binds PICK1 via a PDZ-mediated interaction, which predominantly promotes PICK1 monoubiquitination rather than polyubiquitination. "
    },
    {
      "id": "5318798bb166e2b806000014",
      "ideal_answer": "histone deacetylase inhibitor trichostatin A (TSA), an agent that also targets cancer cells and tumor vasculature. ydroxamic acid (HA)-based histone deacetylase (HDAC) inhibitors, with trichostatin A (TSA) as the reference compound, are potential antitumoral drugs and show promise in the creation of long-term primary cell cultures. Trichostatin A (TSA) is a classic histone deacetylases inhibitor (HDACi) that specifically inhibits the biochemical functions of HDAC and is demonstrated to be an active anticancer drug. the in vitro effects of HDAC inhibitors, such as trichostatin A (TSA), sodium butyrate, depsipeptide (FR901228, FK228), valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), and the demethylating agent, 5-aza-CdR used alone and in combination treatment of human cancer cells. Histone deacetylase (HDAC) inhibitors represent a promising class of potential anticancer agents for treatment of human malignancies. istone deacetylase inhibitors (HDACis) are emerging as a promising new class of anticancer agents displaying growth-inhibitory activity and low toxicity in vivo. e reported a novel potential anticancer strategy by using histone deacetylase (HDAC) inhibitor to enhance the action of endocrine therapy in ERα-positive breast cancer cell. we demonstrated that the HDIs butyrate and trichostatin A (TSA) directly repress c-Src proto-oncogene expression in many cancer cell lines. "
    },
    {
      "id": "531881acb166e2b806000017",
      "ideal_answer": "Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. We have demonstrated that, upon 17-AAG treatment, bladder cancer cells are arrested in the G1 phase of the cell cycle and eventually undergo apoptotic cell death in a dose-dependent manner. In toto, we have evinced the dose-dependent and cell line-specific actions of geldanamycin on cell cycle progression, survival and motility of human bladder cancer cells, due to downregulation of critical Hsp90 clients and subsequent disruption of signaling -oncogenic- integrity. In total, we have clearly evinced a dose-dependent and cell type-specific effect of 17-AAG on cell cycle progression, survival and motility of human bladder cancer cells, due to downregulation of multiple Hsp90 clients and subsequent disruption of signaling integrity. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. Furthermore, 17-AAG administration was shown to induce a pronounced downregulation of multiple Hsp90 protein clients and other downstream effectors, such as IGF-IR, Akt, IKK-α, IKK-β, FOXO1, ERK1/2 and c-Met, resulting in sequestration-mediated inactivation of NF-κB, reduced cell proliferation and decline of cell motility. "
    },
    {
      "exact_answer": [
        [
          "gefitinib"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "Iressa"
        ],
        [
          "Epidermal growth factor receptor inhibitor"
        ],
        [
          "Deferred"
        ]
      ],
      "id": "53188480b166e2b806000018",
      "ideal_answer": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) that causes growth delay in cancer cell lines and human tumor xenografts expressing high levels of EGFR. Gefitinib (Iressa) is a specific and effective epidermal growth factor receptor inhibitor. "
    },
    {
      "exact_answer": [
        [
          "Phosphotransferases"
        ],
        [
          "Imatinib mesylate"
        ],
        [
          "Platelet-Derived Growth Factor Receptor"
        ],
        [
          "tyrosine kinase ABL1"
        ],
        [
          "Proto-Oncogene Protein c-kit"
        ],
        [
          "Minimum"
        ],
        [
          "Fusion Proteins, bcr-abl"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "ABL1 wt Allele"
        ],
        [
          "literary novel"
        ],
        [
          "Manufactured form"
        ],
        [
          "Collapse of Medical Device or Device Component"
        ],
        [
          "Pharmacologic Substance"
        ],
        [
          "Neoplasm"
        ],
        [
          "Cascade Device Component"
        ],
        [
          "Gastrointestinal Stromal Tumors"
        ],
        [
          "Myeloid Leukemia, Chronic"
        ],
        [
          "Downstream"
        ],
        [
          "Signal Transduction"
        ],
        [
          "cell transformation"
        ],
        [
          "Toxic effect"
        ],
        [
          "Relationships"
        ],
        [
          "Toxicity aspects"
        ],
        [
          "Metabolic Inhibition"
        ],
        [
          "Protein-tyrosine kinase inhibitor"
        ],
        [
          "Inhibitor"
        ],
        [
          "Activities"
        ],
        [
          "Cancer Therapeutic Procedure"
        ],
        [
          "Relative"
        ],
        [
          "Clinical Management"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Clinical"
        ],
        [
          "Leptocyte"
        ]
      ],
      "id": "53188992b166e2b806000019",
      "ideal_answer": "Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Its clinical activity and minimal toxicity are related to specific inhibition of cellular targets including BCR-ABL, platelet-derived growth factor receptor and c-kit kinases, resulting in the collapse of downstream signaling cascades important for transformation. Imatinib mesylate is a novel anti-tumor agent useful in the clinical management of chronic myelogenous leukemia and gastrointestinal stromal tumors with minimal toxicity relative to other forms of cancer therapy. "
    },
    {
      "id": "53188c12b166e2b80600001a",
      "ideal_answer": "Alterations in RhoA, RhoB, RhoC, Rac1 and Cdc42 expression play a significant role in the genesis and progression of UCC of the urinary bladder. Published reports suggest that elevated RhoA/Rho-kinase signaling plays a role in the development of benign prostatic hyperplasia, erectile dysfunction, kidney failure, ejaculation disorders, prostate and bladder cancer initiation, and eventual metastasis. By univariate analysis, high RhoA, RhoC, and ROCK protein expression predicted shortened disease-free and overall survival (P \u003c 0.0001). Kaplan-Meier plots linked high RhoA, RhoC, and ROCK protein expression to shortened disease-free and overall survival (P \u003c 0.0001). RhoA, RhoC, and ROCK were more abundant in tumors and metastatic lymph nodes than in nontumor bladder and uninvolved lymph nodes (P \u003c 0.0001). High RhoA, RhoC, and ROCK expression were related to poor tumor differentiation (P \u003c 0.05, P \u003c 0.01, and P \u003c 0.01, respectively), muscle invasion (P \u003c 0.001), and lymph node metastasis (P \u003c 0.05). Overall survival in tumors invading muscle (T2 to T4; 44 patients) was significantly influenced by RhoA, RhoC, and ROCK in a Kaplan-Meier analysis (P \u003c 0.0001, P \u003c 0.0001, and P \u003c 0.01, respectively). "
    },
    {
      "exact_answer": [
        [
          "ERBB2 gene"
        ],
        [
          "Malignant neoplasm of breast"
        ],
        [
          "Positive Finding"
        ],
        [
          "Germ-Line Mutation"
        ],
        [
          "erbB-2 Receptor"
        ]
      ],
      "id": "5318929fb166e2b80600001b",
      "ideal_answer": "Sixty three percent of invasive and 73% of in situ carcinomas were positive for Her2/neu (IHC 3+ or FISH amplified). Breast cancers in TP53 mutation carriers recently have more often been reported to be hormone receptor and HER-2 positive by immunohistochemistry and FISH in small series. As seen in this case, most breast cancers in patients with LFS exhibit a triple-positive phenotype (estrogen receptor-positive/progesterone receptor-positive/HER2-positive). A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%);. Human epidermal growth factor receptor 2 (HER2) amplification and/or overexpression was found in 67% of the tumors from the cases, compared with 25% for the controls (P \u003d .0001). Most DCIS and invasive ductal carcinomas in LFS are hormone receptor positive and/or HER-2 positive. Patients who tested positive for germlineTP53 mutations (n \u003d 30) were compared with controls (n \u003d 79). Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. "
    },
    {
      "exact_answer": [
        [
          "assay qualifier"
        ],
        [
          "Endopeptidases"
        ],
        [
          "Toxin"
        ],
        [
          "Botulinum Toxin Type A"
        ],
        [
          "Human Induced Pluripotent Stem Cells"
        ],
        [
          "Derivation"
        ],
        [
          "Active"
        ],
        [
          "Detection"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Detected (finding)"
        ],
        [
          "Hydrolase"
        ],
        [
          "Gold Colloid"
        ],
        [
          "Neurons"
        ],
        [
          "Singular"
        ],
        [
          "Mouse bioassay"
        ],
        [
          "biological"
        ],
        [
          "Alternative"
        ],
        [
          "Purpose"
        ],
        [
          "Peptides"
        ],
        [
          "Report (document)"
        ],
        [
          "Antibodies, Neutralizing"
        ],
        [
          "Bontoxilysin"
        ],
        [
          "year"
        ],
        [
          "SNAP-25 activity"
        ],
        [
          "CMD1B gene"
        ],
        [
          "Providing (action)"
        ],
        [
          "Functional"
        ],
        [
          "Increased Sensitivy"
        ],
        [
          "Colorimetry"
        ],
        [
          "Food"
        ],
        [
          "literary novel"
        ],
        [
          "Toxigenic"
        ],
        [
          "Microplate Reader"
        ],
        [
          "Neurotoxins"
        ],
        [
          "endopeptidase activity"
        ],
        [
          "Mus"
        ],
        [
          "Biomedical Monitors"
        ],
        [
          "Relational Operator - Equal"
        ],
        [
          "Labels (device)"
        ],
        [
          "Hold - dosing instruction fragment"
        ],
        [
          "Pharmacy (field)"
        ],
        [
          "suggestion"
        ],
        [
          "Abnormally high"
        ],
        [
          "Bioassay Class"
        ],
        [
          "Intoxication"
        ],
        [
          "Histopathologic Grade differentiation"
        ],
        [
          "Toxin typing"
        ],
        [
          "Coating (film)"
        ],
        [
          "Other Toxicity Studies: Mechanistic Studies"
        ],
        [
          "Specimen"
        ],
        [
          "Specimen Type - Serum"
        ],
        [
          "promise"
        ],
        [
          "Various patch test substance"
        ],
        [
          "Technology Platform"
        ],
        [
          "Conjugated"
        ],
        [
          "Ideal"
        ],
        [
          "Plate assay technique"
        ],
        [
          "Lethal"
        ],
        [
          "Toxin assay procedure"
        ],
        [
          "toxin activity"
        ],
        [
          "GOLD STANDARD"
        ],
        [
          "fg/mL"
        ],
        [
          "Chemical Cleavage"
        ],
        [
          "Dual - RoleCode"
        ],
        [
          "Scientific Study"
        ],
        [
          "Entire cell"
        ],
        [
          "Rat Spinal Cord"
        ],
        [
          "Confirm"
        ],
        [
          "Limit of Detection"
        ],
        [
          "Demonstrates"
        ],
        [
          "Mass Spectrometry"
        ],
        [
          "Fast"
        ],
        [
          "Primary operation"
        ],
        [
          "Spectrum Analysis"
        ],
        [
          "UV-VIS Spectrum"
        ],
        [
          "Employed"
        ],
        [
          "Biochemical"
        ],
        [
          "Enzyme Assays"
        ],
        [
          "Internal"
        ],
        [
          "Determination Aspects"
        ],
        [
          "Successful"
        ],
        [
          "Testing"
        ],
        [
          "Laboratory culture"
        ],
        [
          "Cell Differentiation process"
        ],
        [
          "Procedure to identify antibody"
        ],
        [
          "Comparison"
        ],
        [
          "Simple"
        ],
        [
          "High sensitivity"
        ],
        [
          "Research Activities"
        ],
        [
          "Highly sensitive"
        ],
        [
          "Direct type of relationship"
        ],
        [
          "Bioassay, In Vivo"
        ],
        [
          "Greater"
        ],
        [
          "Free (available (qualifier))"
        ],
        [
          "Current (present time)"
        ],
        [
          "Test Method"
        ],
        [
          "In Vitro [Publication Type]"
        ],
        [
          "In Vitro Model"
        ],
        [
          "Potential"
        ],
        [
          "Data"
        ]
      ],
      "id": "531d6bfc267d7dd053000007",
      "ideal_answer": "BoNT/A intoxication studies demonstrate that the hiPSC-derived neurons reproducibly and quantitatively detect biologically active BoNT/A with high sensitivity (EC(50) ∼0.3 U). A label free colorimetric assay for the detection of active botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold. This report demonstrates a novel assay that utilises the endopeptidase activity of the toxin to detect Botulinum neurotoxin in a pharmaceutical sample. The cleaving of SNAP-25 is monitored via UV-Visible spectroscopy with a limit of detection of 373 fg/mL and has been further developed into a high throughput method using a microplate reader detecting down to 600 fg/mL of active toxin. Cell-based assays are currently the only in vitro alternative that detect fully functional BoNTs in a single assay and have been utilized for years for research purposes. Human induced pluripotent stem cells (hiPSC) hold great promise for providing various differentiated cell models for in vitro toxigenicity testing. his study reports the successful use of an enzymatic assay employing an internally quenched fluorogenic peptide as a fast, simple and inexpensive alternative to the mouse bioassay. "
    },
    {
      "exact_answer": [
        [
          "alisertib"
        ],
        [
          "MLN 8237"
        ],
        [
          "Aurora Kinase A"
        ],
        [
          "Investigational"
        ],
        [
          "Inhibitor"
        ]
      ],
      "id": "531dd4af267d7dd05300000d",
      "ideal_answer": "This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral drug MLN8237 (alisertib), a small-molecule Aurora A kinase (AAK) inhibitor, in 87 adult patients with advanced solid tumors. This phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of MLN8237 (alisertib), an investigational, oral, selective AAK inhibitor, in 59 adults with advanced solid tumors. We further find that MLN8237 (Alisertib), a selective inhibitor of AURKA, induced polyploidization and expression of mature megakaryocyte markers in acute megakaryocytic leukemia (AMKL) blasts and displayed potent anti-AMKL activity in vivo. The spindle organization defects induced by alisertib have been used to develop a pharmacodynamic (PD) assay for Aurora A inhibition based on the percentage of mitotic cells with proper chromosomal alignment at the metaphase plate (% aligned spindles, abbreviated as AS). Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. We therefore designed a phase II study of alisertib, a selective AAK inhibitor, in patients with relapsed and refractory aggressive non-Hodgkin lymphomas. "
    },
    {
      "id": "531e01ff267d7dd05300000e",
      "ideal_answer": "The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. "
    },
    {
      "exact_answer": [
        [
          "IMMT gene"
        ],
        [
          "Genus Mino"
        ],
        [
          "Staphylococcal Protein A"
        ],
        [
          "CHCHD3 gene"
        ],
        [
          "Intermembranous space of mitochondrion"
        ],
        [
          "Protein complex"
        ],
        [
          "Organized"
        ],
        [
          "complex (molecular entity)"
        ],
        [
          "Large"
        ],
        [
          "Inner mitochondrial membrane"
        ],
        [
          "MINOS1 gene"
        ],
        [
          "Annexin A2"
        ],
        [
          "Mitochondria"
        ],
        [
          "APOOL gene"
        ],
        [
          "SAMM50 gene"
        ],
        [
          "Requirement"
        ],
        [
          "Type of bridge device"
        ],
        [
          "mitochondrial crista junction"
        ],
        [
          "Subunit"
        ],
        [
          "Mitochondrial cristae"
        ],
        [
          "Architecture as Topic"
        ],
        [
          "Membrane"
        ],
        [
          "Maintenance"
        ],
        [
          "Component object"
        ],
        [
          "Device Component System"
        ],
        [
          "Processor Core"
        ],
        [
          "Constituents"
        ],
        [
          "Contain (action)"
        ],
        [
          "Protein Component"
        ],
        [
          "Proteins"
        ],
        [
          "central element"
        ],
        [
          "Internal"
        ],
        [
          "Term (temporal)"
        ],
        [
          "Formation"
        ],
        [
          "PIEZO1 gene"
        ],
        [
          "TOB1 gene"
        ],
        [
          "S-Adenosylmethionine"
        ],
        [
          "cardiolipin binding"
        ],
        [
          "Connect"
        ],
        [
          "Couple (action)"
        ],
        [
          "mitochondrial sorting and assembly machinery complex"
        ],
        [
          "immunologic"
        ],
        [
          "Partner in relationship"
        ],
        [
          "Integral Membrane Proteins"
        ],
        [
          "Retained"
        ],
        [
          "outer membrane"
        ],
        [
          "inner membrane complex"
        ],
        [
          "Qualitative form"
        ],
        [
          "Lacking"
        ],
        [
          "Exist"
        ],
        [
          "Physical shape"
        ],
        [
          "Core Device Component"
        ],
        [
          "Providing (action)"
        ],
        [
          "Mutant"
        ],
        [
          "findings aspects"
        ],
        [
          "Generation (action)"
        ],
        [
          "Domain (area of knowledge)"
        ],
        [
          "Component (part)"
        ],
        [
          "Additional"
        ],
        [
          "Interaction"
        ],
        [
          "Carboxy-Terminal Amino Acid"
        ],
        [
          "Direct (qualifier)"
        ],
        [
          "Tissue membrane"
        ],
        [
          "Structure"
        ],
        [
          "Evidence of"
        ],
        [
          "System"
        ],
        [
          "Study"
        ]
      ],
      "id": "53215fca9b2d7acc7e000005",
      "ideal_answer": "To study if outer membrane interactions and maintenance of cristae morphology are directly coupled, we generated mutant forms of mitofilin/Fcj1 (formation of crista junction protein 1), a core component of MINOS. We provide evidence that the SAM components exist in a large protein complex together with the IMM proteins mitofilin and CHCHD3, which we term the mitochondrial intermembrane space bridging (MIB) complex. The mitochondrial inner membrane organizing system (MINOS) is a large protein complex required for maintaining inner membrane architecture. The mitochondrial inner membrane contains a large protein complex crucial for membrane architecture, the mitochondrial inner membrane organizing system (MINOS). and the mitochondrial structural proteins-components of mitochondrial inter-membrane space bridging (MIB) complex (Mitofilin, Sam50, and ChChd3),. which we term MitOS for mitochondrial organizing structure, comprised of Fcj1/Mitofilin, a conserved inner membrane protein, and five additional components. APOOL is a cardiolipin-binding constituent of the Mitofilin/MINOS protein complex. Mitofilin is part of a large inner membrane complex, and we identify five partner proteins as constituents of the mitochondrial inner membrane organizing system (MINOS) that is required for keeping cristae membranes connected to the inner boundary membrane. Mitochondria lacking mitofilin, the large core subunit of MINOS,. Mitofilin/MINOS protein complex. "
    },
    {
      "exact_answer": "yes",
      "id": "5321ae889b2d7acc7e000006",
      "ideal_answer": "As reported below, although this symptom may well be diagnostically misleading, careful diagnosis based on clinical signs may distinguish patients with BMS from those with reflux disease, and successful management of burning mouth is often enables. Our results suggest that there is no causal connection between LPR episodes and the occurrence of intraoral burning sensations in the examined patients. "
    },
    {
      "exact_answer": "yes",
      "id": "5321b4959b2d7acc7e000007",
      "ideal_answer": "On the contrary, altered TERalb and increased carotid artery intimal thickness are shown by all hypertensive type 2 diabetic patients, both with normal and altered patterns of AER. Altered systemic capillary permeability characterizes insulin-resistant hypertensive patients with Metabolic Syndrome. TERalb is increased in normo-albuminuric type 1 diabetic patients. "
    },
    {
      "exact_answer": "yes",
      "id": "5321b8a39b2d7acc7e000009",
      "ideal_answer": "Moreover, the increased susceptibility of the glomerular capillaries in diabetics to ANP seems to be part of a more generalized capillary abnormality, because ANP also increases the transcapillary escape of albumin. Thus, in a large ethnically homogeneous cohort of diabetic subjects, our data show: (1) a significant association of C708/T polymorphism with microalbuminuria in long-term diabetes and with both lower plasma ANP levels and widespread albumin leakage. In summary, low dose ANP infusion in healthy subjects caused a shift of plasma water and electrolytes from the circulation, with albumin escape as a secondary phenomenon. hese results suggest a possible role of PND gene in conferring protection from nephropathy and microvascular damage in type 1 diabetes. "
    },
    {
      "exact_answer": "yes",
      "id": "5321bb019b2d7acc7e00000b",
      "ideal_answer": "fT3 and low-T3 syndrome are significantly related to NT-pro-BNP in patients with cardiovascular disease, but are predictors of mortality independently of NT-pro-BNP and other known cardiovascular risk parameters. fter adjustment for known confounders, NT-pro-BNP was significantly associated with fT3 and low-T3 syndrome. were predictive for mortality after adjustment for NT-pro-BNP levels and other cardiovascular prognostic variables. BNP and fT3 are independently associated with exercise capacity in severely compromised HF patients. Higher NT-pro BNP concentrations were related to lower total T3 concentrations (r \u003d -0.294,. and low-T3 syndrome (HR 3.0, 95%CI 1.4-6.3). p \u003d 0.011) and to higher reverse T3 concentrations (r \u003d 0.353, p \u003d 0.002). fT3 (HR 0.58, 95%CI 0.34-0.98). "
    },
    {
      "exact_answer": [
        [
          "Phosphatidylinositol 3-Kinases"
        ],
        [
          "Idelalisib"
        ],
        [
          "Phosphotransferases"
        ],
        [
          "Inhibitor"
        ],
        [
          "Specific qualifier value"
        ]
      ],
      "id": "5321bc309b2d7acc7e00000d",
      "ideal_answer": "PI3Kδ (idelalisib). Idelalisib (PI3K inhibitor). In the last few years, several classes of potent and selective small molecule PI3K inhibitors have been developed, and at least fifteen compounds have progressed into clinical trials as new anticancer drugs. idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform. idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. PI3K inhibitor idelalisib. the PI3K inhibitor idelalisib. PI3K-δ inhibitor idelalisib. Among these, idelalisib. "
    },
    {
      "id": "5322d9339b2d7acc7e000011",
      "ideal_answer": "These results show that RIα inactivation leads to multiple, compartment-specific alterations of the cAMP/PKA pathway revealing new aspects of signaling dysregulation in tumorigenesis. Suppression of protein kinase A regulatory subunit 1 alpha (PRKAR1A) has been proven to inhibit cholangiocarcinoma (CCA) cell growth and enhance apoptosis. Knockdown of the cAMP-dependent protein kinase (PKA) Type Ialpha regulatory subunit in mouse oocytes disrupts meiotic arrest and results in meiotic spindle defects. Silencing PRKAR1A expression induced growth inhibition and apoptosis of CCA cells, with an associated decrease in mitogen-activated protein kinases, PI3K/Akt, JAK/STAT and Wnt/β-catenin pathway signaling. These results demonstrate that RIalpha is required for regulating PKA activity in maturing oocytes and that compensatory upregulation of RII does not occur. abrogation of gene expression caused significant CCA cell growth inhibition, oncogenic signaling and coupled apoptosis induction. The inhibition of PKA using a PKA inhibitor and cAMP analogs also led to a significant cell growth inhibition. "
    },
    {
      "exact_answer": "yes",
      "id": "5322de919b2d7acc7e000012",
      "ideal_answer": "Tear proteomic analysis of patients with type 2 diabetes and dry eye syndrome by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. Dry eye syndrome in diabetic patients is associated with aberrant expression of tear proteins, and the findings could lead to identification of novel pathways for therapeutic targeting and new diagnostic markers. This study demonstrated that iTRAQ technology combined with 2D-nanoLC-nanoESI-MS/MS quantitative proteomics is a powerful tool for biomarker discovery. 2D electrophoresis (2DE) and Differential gel electrophoresis (DIGE) was done to identify differentially expressed proteins. Two dimensional electrophoretic analysis of human tears: collection method in dry eye syndrome. "
    },
    {
      "exact_answer": [
        [
          "Thick"
        ],
        [
          "Wall of bladder"
        ],
        [
          "Measurement"
        ],
        [
          "Ultrasonography"
        ],
        [
          "Walls of a building"
        ]
      ],
      "id": "5324bdba9b2d7acc7e00001a",
      "ideal_answer": "Modifications of the bladder wall (organ damage) in patients with bladder outlet obstruction: ultrasound parameters. Also conventional US detects established signs of bladder damage: diverticulosis, trabecolations in the bladder wall (pseudo-diverticula),. Preliminary data on the automatic measurement of bladder wall thickness were reported, suggesting a good repeatability and agreement with conventional ultrasound imaging. conventional ultrasound bladder wall thickness (BWT) measurements. To identify measurements of ultrasonography (US)-derived bladder wall thickness (BWT). Ultrasonographic assessment of bladder wall thickness is a sensitive screening tool. ultrasound for bladder wall thickness (BWT). Transabdominal ultrasonography with a high-frequency probe was performed to obtain the anterior, posterior, and lateral bladder wall thicknesses. transabdominal ultrasonography for bladder volume and detrusor muscle thickness. Measurement of the bladder wall thickness (BWT) or detrusor wall thickness (DWT) by US is reliable,. ultrasonography-estimated bladder weight and bladder wall thickness. The measurement of a mean bladder wall thickness greater than 5 mm with transvaginal ultrasound. BladderScan BVM 9500 device (Diagnostic Ultrasound, Bothell, WA) was used to measure bladder wall thickness. Transvaginal ultrasound measurement of bladder wall thickness:. ultrasound (US) techniques to measure bladder wall thickness (BWT). ultrasound bladder and detrusor wall thickness. "
    },
    {
      "exact_answer": [
        [
          "Integer +2"
        ],
        [
          "Mobile Applications"
        ],
        [
          "Alcohols"
        ],
        [
          "Amyloid Beta Precursor Protein Measurement"
        ],
        [
          "Reference Object"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Allopathic \u0026 Osteopathic Physicians - Dermatology"
        ],
        [
          "calculator"
        ],
        [
          "Integer +5"
        ],
        [
          "Availability of"
        ],
        [
          "Helping Behavior"
        ],
        [
          "Journal"
        ],
        [
          "ToDay brand"
        ],
        [
          "Review [Publication Type]"
        ],
        [
          "Ultraviolet Rays"
        ],
        [
          "chain of objects"
        ],
        [
          "Promotion (action)"
        ],
        [
          "twenty twenty"
        ],
        [
          "Preventive monitoring"
        ],
        [
          "Involvement with"
        ],
        [
          "Laboratory"
        ],
        [
          "Internal-External Locus of Control Scale"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Behavioral change"
        ],
        [
          "Real Time"
        ],
        [
          "strategy"
        ],
        [
          "Identified"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Weight Loss Adverse Event"
        ],
        [
          "Diagnosis"
        ],
        [
          "Evidence of"
        ],
        [
          "Sunscreening Agents"
        ],
        [
          "Preposition For"
        ],
        [
          "Body Weight decreased"
        ],
        [
          "subscriber - self"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Alcohol consumption"
        ],
        [
          "Reminding"
        ],
        [
          "Dermoscopy"
        ],
        [
          "photograph"
        ],
        [
          "literary novel"
        ],
        [
          "Educational Psychologist - NUCCProviderCodes"
        ],
        [
          "Conferences"
        ],
        [
          "Kidney Calculi"
        ],
        [
          "Dermatology field"
        ],
        [
          "News [Publication Type]"
        ],
        [
          "Drink (dietary substance)"
        ],
        [
          "Alcohol Abstinence"
        ],
        [
          "Pharmacy (field)"
        ],
        [
          "Recommendation"
        ],
        [
          "Abnormally high"
        ],
        [
          "Telephone Device Component"
        ],
        [
          "Ecology"
        ],
        [
          "Harm Reduction"
        ],
        [
          "Call (Instruction)"
        ],
        [
          "Sharing (Social Behavior)"
        ],
        [
          "Productivity"
        ],
        [
          "Minority Groups"
        ],
        [
          "Cover - action"
        ],
        [
          "biologic consumption"
        ],
        [
          "Act Code - General"
        ],
        [
          "user - individual"
        ],
        [
          "Tracking"
        ],
        [
          "Fitness"
        ],
        [
          "Healthy Eating"
        ],
        [
          "Education, Medical, Continuing"
        ],
        [
          "Prone Position"
        ],
        [
          "Prophylactic treatment"
        ],
        [
          "Scientific Equipment"
        ],
        [
          "Water Specimen"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Component object"
        ],
        [
          "Mobile Health"
        ],
        [
          "Team"
        ],
        [
          "Drinking behavior processes"
        ],
        [
          "alcoholism/alcohol abuse education"
        ],
        [
          "Categories"
        ],
        [
          "Educational Status"
        ],
        [
          "Professional guide"
        ],
        [
          "Health Professional"
        ],
        [
          "Medical Surveillance"
        ],
        [
          "Changing"
        ],
        [
          "information collection"
        ],
        [
          "Recovery - healing process"
        ],
        [
          "Storage"
        ],
        [
          "Large prostate"
        ],
        [
          "Devices"
        ],
        [
          "Pediatric Obesity"
        ],
        [
          "Persons"
        ],
        [
          "Flow of urine"
        ],
        [
          "Pathology processes"
        ],
        [
          "Address"
        ],
        [
          "Child"
        ],
        [
          "S-Phase Fraction"
        ],
        [
          "Relationships"
        ],
        [
          "Positive Finding"
        ],
        [
          "prevention aspects"
        ],
        [
          "3/5"
        ],
        [
          "Self Monitoring"
        ],
        [
          "Daily"
        ]
      ],
      "id": "5324cca79b2d7acc7e00001d",
      "ideal_answer": "A total of 229 dermatology-related apps were identified in the following categories: general dermatology reference (61 [26.6%]), self-surveillance/diagnosis (41 [17.9%]), disease guide (39 [17.0%]), educational aid (20 [8.7%]), sunscreen/UV recommendation (19 [8.3%]), calculator (12 [5.2%]), teledermatology (8 [3.5%]), conference (6 [2.6%]), journal (6 [2.6%]), photograph storage/sharing (5 [2.2%]), dermoscopy (2 [0.9%]), pathology (2 [0.9%]), and other (8 [3.5%]). Today, many high quality mobile apps are available for users and health professionals and cover the whole health care chain, i.e. information collection, prevention, diagnosis, treatment and monitoring. to examine the current available mobile smartphone applications (e.g., apps) that utilize principles of ecological momentary assessment (EMA)-daily self-monitoring or near real-time self-assessment of alcohol-use behavior-to promote positive behavior change, alcohol harm reduction, psycho-education about alcohol use, or abstinence from alcohol. Twenty-seven mobile apps were identified and reviewed that involved general pharmacy practice, including apps that involved drug references, clinical references, medical calculators, laboratory references, news and continuing medical education, and productivity. More than 17,000 mHealth apps now are available for smart phones and other devices, and they do everything from monitoring urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink more water. "
    },
    {
      "exact_answer": [
        [
          "Fibromyalgia"
        ],
        [
          "Amitriptyline"
        ],
        [
          "pregabalin"
        ],
        [
          "Neuralgia"
        ],
        [
          "Antiepileptic Agents"
        ]
      ],
      "id": "5324ce779b2d7acc7e00001e",
      "ideal_answer": "Amitriptyline should continue to be used as part of the treatment of neuropathic pain or fibromyalgia, but only a minority of patients will achieve satisfactory pain relief. Amitriptyline is a tricyclic antidepressant that is widely used to treat chronic neuropathic pain (pain due to nerve damage) and fibromyalgia, and is recommended in many guidelines. Valproic acid and its sodium salt (sodium valproate) are antiepileptic drugs that are sometimes used to treat chronic neuropathic pain and fibromyalgia, although they are not licensed for this use. Oral pregabalin, a calcium channel alpha(2)delta-subunit ligand with analgesic, anxiolytic and antiepileptic activity, has shown efficacy in the treatment of fibromyalgia. Pregabalin is, therefore, a valuable option in the first-line treatment of patients with fibromyalgia. A multidisciplinary program was developed and implemented for patients with fibromyalgia in the primary care setting. Multimodal approaches seem to be the treatment of choice in fibromyalgia. Amitriptyline for neuropathic pain and fibromyalgia in adults. The program included education (seven sessions) and physical therapy (25 sessions). "
    },
    {
      "exact_answer": [
        [
          "duloxetine"
        ],
        [
          "Labels (device)"
        ],
        [
          "Antidepressive Agents"
        ],
        [
          "Trazodone"
        ],
        [
          "Selective Serotonin Reuptake Inhibitors"
        ],
        [
          "Fluoxetine"
        ],
        [
          "Sertraline"
        ],
        [
          "Aminobutyric Acid"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Prescribed"
        ],
        [
          "dapoxetine"
        ],
        [
          "Fluvoxamine"
        ],
        [
          "Preposition For"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Hot flushes"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Sleeplessness"
        ],
        [
          "Negation"
        ],
        [
          "Fibromyalgia"
        ],
        [
          "Frequent"
        ],
        [
          "Lacking"
        ],
        [
          "pregabalin"
        ],
        [
          "Paroxetine"
        ],
        [
          "Singular"
        ],
        [
          "tianeptine"
        ],
        [
          "Benzodiazepines"
        ],
        [
          "Clonidine"
        ],
        [
          "Serotonin Reuptake Inhibitor [EPC]"
        ],
        [
          "Mirtazapine"
        ],
        [
          "Pregnancy"
        ],
        [
          "Escitalopram"
        ],
        [
          "prescription document"
        ],
        [
          "Citalopram"
        ],
        [
          "Randomized Controlled Trials as Topic"
        ],
        [
          "Amitriptyline"
        ],
        [
          "endoplasmic reticulum-Golgi intermediate compartment"
        ],
        [
          "Adolescent (age group)"
        ],
        [
          "Dementia"
        ],
        [
          "Labeling Activity"
        ],
        [
          "Tricyclic antidepressant measurement"
        ],
        [
          "shared attribute"
        ],
        [
          "Proven findings"
        ],
        [
          "Anxiety about treatment"
        ],
        [
          "Sexual Dysfunction"
        ],
        [
          "Gonadal Steroid Hormones"
        ],
        [
          "Urinary Stress Incontinence"
        ],
        [
          "Child"
        ],
        [
          "Randomized Controlled Trial (publication)"
        ],
        [
          "Numerous"
        ],
        [
          "Effectiveness"
        ],
        [
          "Conclude Resin"
        ],
        [
          "Alternative"
        ],
        [
          "Drug Labeling"
        ],
        [
          "Purpose"
        ],
        [
          "Behavior"
        ],
        [
          "Rapid"
        ],
        [
          "Anxiety Disorders"
        ],
        [
          "Evaluation"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Male population group"
        ],
        [
          "Experimental Result"
        ],
        [
          "United States Food and Drug Administration"
        ],
        [
          "Pharmacotherapy"
        ],
        [
          "Compound (substance)"
        ],
        [
          "Possible diagnosis"
        ],
        [
          "Safety Study"
        ],
        [
          "year"
        ],
        [
          "Daily"
        ],
        [
          "Approved"
        ],
        [
          "mechanism of action qualifier"
        ],
        [
          "Current (present time)"
        ],
        [
          "Patients"
        ],
        [
          "pharmacotherapeutic"
        ],
        [
          "Obsolete - EditStatus"
        ],
        [
          "Hypnotics"
        ],
        [
          "PSD 502"
        ],
        [
          "Authorized - ActCode"
        ],
        [
          "Off-Label Use"
        ],
        [
          "Ejaculation"
        ],
        [
          "Premature Ejaculation"
        ],
        [
          "Bulimia"
        ],
        [
          "Prompting"
        ],
        [
          "Gynecology"
        ],
        [
          "Diabetic Neuropathies"
        ],
        [
          "vasomotor symptom"
        ],
        [
          "Cystectomy"
        ],
        [
          "Contraindicated"
        ],
        [
          "Drug Overdose"
        ],
        [
          "Preferred - Specimen Appropriateness"
        ],
        [
          "Central Minus"
        ],
        [
          "Erectile Dysfunction Adverse Event"
        ],
        [
          "Breastfeeding (mother)"
        ],
        [
          "Radical prostatectomy"
        ],
        [
          "Reuptake Inhibitors"
        ],
        [
          "With - dosing instruction fragment"
        ],
        [
          "Menopause"
        ],
        [
          "Benzodiazepine dependence"
        ],
        [
          "Menopausal syndrome"
        ],
        [
          "Pelvic floor exercises"
        ],
        [
          "Psychotherapy"
        ]
      ],
      "id": "5324cf139b2d7acc7e00001f",
      "ideal_answer": "different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs). Other off-label uses include the treatment of bulimia, benzodiazepine/alcohol dependence, fibromyalgia, central nervous system degenerative diseases (behavioral disorders in dementia and other organic disorders), schizophrenia, chronic pain disease and diabetic neuropathy, sexual dysfunction. Fluvoxamine was the most prescribed antidepressant for the treatment of anxiety disorders and mixed disorders of emotions and conduct. Although there are numerous reports on the off-label use of selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI). Hormone replacement therapy is often contraindicated and there are non-hormonal treatments that are proven to be more effective than placebo in randomized controlled trials, e.g., some antidepressants, gabapentine and clonidine. Given the presumed efficacy of these new compounds and the off-label use of the current SSRIs, one might conclude that psychotherapy\\behavior therapy for rapid ejaculation is an obsolete and antiquated intervention. In the treatment of mood and anxiety disorders during pregnancy, the serotonin reuptake inhibitors are often preferred over tricyclic antidepressants because of their relatively few adverse effects and safety in overdose. "
    },
    {
      "exact_answer": "yes",
      "id": "5324cf869b2d7acc7e000020",
      "ideal_answer": "To analyze whether the time (morning/evening) of administration of a compound containing 60 mg of dry soy seed extract (glycine max) with 40% of total isoflavones, primrose oil and α-tocopherol modifies the effect on the climacteric syndrome. Our search identified 58 randomised controlled trials of which 11 involved the use of clonidine, six for SSRIs, four for gabapentin, seven for black cohosh, seven for red clover, 18 for phytoestrogens, two for ginseng, one for evening primrose,. The object of this study was to evaluate the effect of different doses of a compound containing isoflavones 60 mg, primrose oil 440 mg and vitamin E 10 mg. The application of oral evening primrose oil compared with placebo for controlling hot flashes may decrease more the intensity of attacks. The aim of this study was to compare the efficacy of evening primrose with placebo in improvement of menopausal hot flashes. To evaluate the efficacy of gamolenic acid provided by evening primrose oil in treating hot flushes and sweating associated with the menopause. Nonprescription therapies reviewed include black cohosh, dong quai, evening primrose oil, physical activity, phytoestrogens, and red clover. "
    },
    {
      "exact_answer": [
        [
          "Finasteride"
        ],
        [
          "United States Food and Drug Administration"
        ],
        [
          "Approved"
        ],
        [
          "Androgenetic Alopecia"
        ],
        [
          "Propecia"
        ],
        [
          "Minoxidil"
        ],
        [
          "Dutasteride"
        ],
        [
          "Alopecia"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Male population group"
        ],
        [
          "Cleared by"
        ],
        [
          "United States"
        ],
        [
          "Current (present time)"
        ],
        [
          "Preposition For"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Negation"
        ],
        [
          "Combing of hair"
        ],
        [
          "Minoxidil Topical Product"
        ],
        [
          "Minoxidil Topical Solution"
        ],
        [
          "Finasteride Oral Tablet"
        ],
        [
          "Finasteride 1 MG"
        ],
        [
          "literary novel"
        ],
        [
          "Phototherapy"
        ],
        [
          "Singular"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Hold - dosing instruction fragment"
        ],
        [
          "Recommendation"
        ],
        [
          "FDA Approval"
        ],
        [
          "Abnormally low (qualifier value)"
        ],
        [
          "prescription document"
        ],
        [
          "Pharmacologic Substance"
        ],
        [
          "Promotion (action)"
        ],
        [
          "Hair Specimen"
        ],
        [
          "Line Specimen"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Topical surface"
        ],
        [
          "Indication of (contextual qualifier)"
        ],
        [
          "Modality"
        ],
        [
          "5-alpha Reductase Inhibitor [EPC]"
        ],
        [
          "Twice a day"
        ],
        [
          "Medical Devices"
        ],
        [
          "Laser Device Component"
        ],
        [
          "Woman"
        ],
        [
          "Daily"
        ],
        [
          "Phase 3 Clinical Trials"
        ],
        [
          "Oral"
        ],
        [
          "Male Gender, Self Report"
        ],
        [
          "Treated with"
        ],
        [
          "First-Line Therapy"
        ],
        [
          "Type 1"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "First (number)"
        ],
        [
          "Patients"
        ],
        [
          "On (qualifier value)"
        ],
        [
          "/mL"
        ],
        [
          "Drugs, Non-Prescription"
        ]
      ],
      "id": "5324d0169b2d7acc7e000022",
      "ideal_answer": "Recently, in addition to the two currently approved U.S. Food and Drug Administration (FDA) medications (minoxidil and finasteride), a novel device was FDA-approved for the treatment of hair loss, the laser hair comb. Currently there are two U.S. Food and Drug Administration (FDA)-approved agents that promote hair regrowth: over-the-counter topical minoxidil solution for men and women and prescription oral finasteride tablets for men. Finasteride (Propecia) was approved by the FDA in 1998 for treating men with androgenetic alopecia. Topical monoxidil and oral finasteride are commonly in use and have FDA approval for the treatment of male androgenetic alopecia; dutasteride, a type I and II 5-alpha-reductase inhibitor, is on hold in Phase III trials. The only FDA-approved dermatological indication of finasteride is androgenetic alopecia. Topical minoxidil 2%-5% 1 mL twice daily or finasteride 1 mg daily are recommended as first line treatments, followed by the use of Food and Drug Administration-cleared HairMax LaserComb® in patients who do not respond to first line modalities. In addition, low-level light therapy (LLLT) has recently been approved by the United States Food and Drug Administration (FDA) for the treatment of hair loss. "
    },
    {
      "id": "5324d0429b2d7acc7e000023",
      "ideal_answer": "Only 2% of prescribers reported complications other than local irritation that they associated with topical minoxidil therapy, but underreporting of noncutaneous side effects in this survey of dermatologists cannot be excluded. hypertrichosis is uncommon after treatment with topical minoxidil for alopecia, and normally only occurs in areas close to the site of application. A 16-year-old girl is presented who developed generalized hypertrichosis 3 months after applying topical minoxidil for treatment of diffuse alopecia in doses greater than that prescribed. Typical side effects of this topical treatment include irritative dermatitis going along with pruritus, erythema, scaling and dryness, which occur especially at the onset of the therapy. An increased occurrence of pruritus, local irritation, and hypertrichosis was observed with 5% topical minoxidil versus 2% topical minoxidil and placebo. While most of the patients with allergic contact dermatitis described in the literature showed a positive sensitization to the vehicle substance propylene glycol evaluated by patch testing, reactions to the active ingredient minoxidil are rare. We observed an as yet unreported \"polymyalgia syndrome\" in four otherwise healthy males whose sole medication was topically applied minoxidil. The incidence of adverse effects such as pruritus or local irritation was similar in the 5% minoxidil group. "
    },
    {
      "id": "5324d12b9b2d7acc7e000024",
      "ideal_answer": "Since the participation of gluten in the esophageal symptoms of CD seems clear, its intimate mechanisms have yet to be elucidated, and several hypothesis have been proposed, including the specific immune alterations characterizing CD, the reduction in nutrient absorption determining the arrival of intact gluten to distal gastrointestinal segments, and various dysregulations in the function of gastrointestinal hormones and peptides. The present study is the first to have evaluated the effect of a GFD in the nonerosive form of GERD in CD patients, by means of clinical long-term follow-up, suggesting that GFD could be a useful approach in reducing GERD symptoms and in the prevention of recurrence. There is a great interest in the role of a major dietary protein, gluten, in the production of symptoms. several published studies have consistently shown the efficacy of a gluten-free diet in rapidly controlling esophageal symptoms and in preventing their recurrence. We aimed to assess the prevalence of GERD symptoms at diagnosis and to determine the impact of the gluten-free diet (GFD). The GFD is associated with a rapid and persistent improvement in reflux symptoms that resembles the healthy population. "
    },
    {
      "id": "5325b0419b2d7acc7e000026",
      "ideal_answer": "patients with \"systemic nickel allergy syndrome\" (SNAS), characterized by Ni-allergic contact dermatitis and systemic reactions after eating Ni-rich food. Systemic (gastrointestinal and skin) reactions to ingestion of nickel rich foods in patients with nickel allergic contact dermatitis characterize Systemic Nickel Allergy Syndrome (SNAS). Some patients with nickel (Ni) allergic contact dermatitis (ACD) suffer from systemic symptoms after ingestion of Ni-rich foods, a condition termed Systemic Nickel Allergy Syndrome (SNAS). Some patients with nickel (Ni) allergic contact dermatitis suffer from systemic (intestinal or cutaneous) symptoms after ingestion of Ni-rich foods and experience symptoms reduction with low-Ni diet, a condition termed Systemic Ni Allergy Syndrome (SNAS). \"systemic nickel allergy syndrome\" (SNAS), characterized by urticaria/angioedema and gastrointestinal symptoms correlated to the ingestion of nickel-containing foods. Sistemic Nickel Allergy Syndrome (SNAS) consisting of urticaria-like troubles, itch, erythema, cutaneous rush, headache, intestinal symptoms, recurrent vesicular palmar dermatitis. A severe form of this allergy is the Systemic nickel allergy syndrome, clinically characterized by cutaneous manifestions (contact dermatitis, pompholyx, hand dermatitis dyshydrosis, urticaria) with chronic course and systemic symptoms (headache, asthenia, itching, and gastrointestinal disorders related to histopathological alterations of gastrointestinal mucosa, borderline with celiac disease). "
    },
    {
      "exact_answer": "yes",
      "id": "5325de7d9b2d7acc7e000029",
      "ideal_answer": "Increased rT3 may be more common in ESRD patients than previously described, and together with decreased T3 it may serve as an indicator of poor prognosis in subsequent months. Low-T3 syndrome is a frequent finding among HD patients, but it does not predict outcome. The presence of TFT alterations seems to not be associated with clinical and prognostic implications in AKI patients. These data suggest that low FT3 levels are not predictive for mortality in a subgroup of stable HD patients who could survive more than 12 months. Low fT3 is an independent predictor of death in hemodialysis patients. Low T3 was particularly common (44.3 %), and clearly associated with increased 6- and 12-month mortality and decreased overall survival (log rank test, P\u003d0.007). In the Cox regression analysis, low T3 was an independent predictor of all-cause mortality even after adjusting for traditional risk factors (hazard ratio\u003d3.76,. In CKD patients with proteinuria, low T3 concentration predicted all-cause mortality and cardiovascular event independently of the severity of proteinuria. "
    },
    {
      "exact_answer": [
        [
          "Implantation procedure"
        ],
        [
          "Pelvic floor exercises"
        ],
        [
          "Choose (action)"
        ],
        [
          "Options"
        ],
        [
          "Invasive"
        ]
      ],
      "id": "5325fdf0600967d132000001",
      "ideal_answer": "BAUS implantation is a safe, effective, minimally invasive option for iatrogenic male incontinence due to ISD. The bone anchored suburethral synthetic sling is a simple and attractive procedure that can produce immediate good results with low morbidity, especially when strictly selected patients are treated. Properly selected and informed patients can also be treated efficiently with minimally invasive procedures such as the implantation of a male suburethral sling, although the experience with such devices is not extensive. The initial treatment for SUI that persists after 12 months consists of conservative measures such as pelvic floor muscle exercises and behavioral therapy. The artificial urethral sphincter has represented, until today, the gold standard but, in the recent years, sling systems have been investigated as minimally invasive alternative options. Today, three different sling procedures are commonly performed: bone-anchored, readjustable, and trans-obturator slings systems. However, the implantation of artificial urinary sphincter is the gold standard therapy. treatments such as periurethral injection of bulking agents, artificial urinary sphincter (AUS) implantation, and sub-urethral sling positioning. It compares favourably with AUS. "
    },
    {
      "exact_answer": [
        [
          "P Blood group antibodies"
        ],
        [
          "Low T3 Syndrome"
        ],
        [
          "Percent normal"
        ],
        [
          "Interleukin-6, human"
        ],
        [
          "Tumor Necrosis Factors"
        ]
      ],
      "id": "53261e79600967d132000003",
      "ideal_answer": "Considering normal subjects, patients without and with low T3 syndrome, IL-6 and TNFalpha increased progressively from normal to patients with fT3\u003c2 pg/ml (p\u003c0.01 and p\u003c0.01) while CRP only respect to the group with low T3 syndrome (p\u003c0.01). The inflammatory markers were all inversely correlated with FT3 levels. "
    },
    {
      "id": "532624ae600967d132000005",
      "ideal_answer": "Renal sympathetic denervation delivers not only a decrease in blood pressure levels but also renal as well as systemic sympathetic nerve activity. Clinical evaluation of selective renal sympathetic denervation demonstrated a decrease of renal norepinephrine spillover and renin activity, an increase of renal plasma flow, and has confirmed clinically significant, sustained reductions in blood pressure in patients with resistant hypertension. Early clinical evaluation with catheter-based, selective renal sympathetic denervation in patients with resistant hypertension has mechanistically correlated sympathetic efferent denervation with decreased renal norepinephrine spillover and renin activity, increased renal plasma flow, and has demonstrated clinically significant, sustained reductions in blood pressure. The SYMPLICITY HTN-3 Trial is a pivotal study designed as a prospective, randomized, masked procedure, single-blind trial evaluating the safety and effectiveness of catheter-based bilateral renal denervation for the treatment of uncontrolled hypertension despite compliance with at least 3 antihypertensive medications of different classes (at least one of which is a diuretic) at maximal tolerable doses. Small studies suggest that RSD can produce dramatic blood pressure reductions: In the randomized Symplicity HTN-2 trial of 106 patients, the mean fall in blood pressure at 6 months in patients who received the treatment was 32/12 mm Hg. "
    },
    {
      "exact_answer": "yes",
      "id": "532627d0d6d3ac6a34000001",
      "ideal_answer": "The decision to perform the only efficient procedure, i.e., a ventricular shunt operation, depends upon a number of established arguments in favor of that procedure. Three patients deteriorated, eleven remained stable and sixteen showed significant improvement on psychological tests, mainly those for attention, motor speed and memory, but rarely did any improvement of intelligence occur. Clinical improvement depends not only on the capability to restore the cerebrospinal fluid dynamic, but also on the ability of cerebral parenchyma to recover the metabolic function. After shunting, the global CMRglu significantly increased (2.95 ± 0.44 vs 4.38 ± 0.68, p \u003d 10(-7)) in all INPH patients with a mean percentage value of 48.7%. During the 1st postoperative year, there was improvement in the condition of 22 patients (96%) who had received a ventricular shunt; 21 of these patients (91%) remained improved until death or for at least 5 years. Our preliminary data show that changes in the CMRglu are promptly reversible after surgery and that there is a relationship between the early metabolic changes and clinical symptoms, independently from the simultaneous changes in the ventricular size. "
    },
    {
      "exact_answer": [
        [
          "cubic foot"
        ],
        [
          "Postoperative Period"
        ],
        [
          "P Blood group antibodies"
        ],
        [
          "Abnormally high"
        ],
        [
          "P prime"
        ]
      ],
      "id": "53265dd4d6d3ac6a34000007",
      "ideal_answer": "There was a significant inverse relationship between fT3 levels and global oxygen consumption. This group also had a significantly higher score on The Pediatric Risk of Mortality (PRISM; P \u003c 0.042) and a longer duration of ventilation (P \u003c 0.014). In a group of elderly patients undergoing cardiac surgery, there was a strong association between a postoperative decrease of serum triiodothyronine levels and atrial fibrillation. Those with an uneventful recovery had a higher serum free T4 level on the sixth day after operation than those with complications. A relevant finding was that the days of post-operative hospitalization (10+/-3 days, means+/-S.D.) was inversely correlated with the slope of the recovery of T3 concentration (P\u003c0.001) or with the area under the plasma curves of T3 (P\u003d0.024,. Low basal fT3 concentration can reliably predict the occurrence of postoperative AF in CABG patients. Enhancement of T3 levels after mitral valve replacement may increase the probability of early spontaneous cardioversion of AF, but can not affect the duration of sinus rhythm. Patients with fT3 syndrome had the highest mortality (16.7%, NS), highest incidence of acute rejection (38.9%,. SCH appears to influence the postoperative outcome for patients by increasing the development of postoperative atrial fibrillation. "
    },
    {
      "exact_answer": [
        [
          "Albumins"
        ],
        [
          "P Blood group antibodies"
        ],
        [
          "Postoperative Period"
        ],
        [
          "Low T3"
        ],
        [
          "Conclude Resin"
        ]
      ],
      "id": "532670e7d6d3ac6a34000008",
      "ideal_answer": "In on-pump CABG surgery, inflammatory effects encompass activation of total leukocytes, neutrophils and platelets, reduction of serum level of total proteins and albumin and decreased thyroid hormones levels, especially within first postoperative 24 hours. FT3 concentration dropped significantly (p \u003c 0.0001), reaching its lowest value 12 hours postoperatively. Typical NTIS was observed in all patients, and the FT3 concentration was still reduced by postoperative day 5 (p\u003c0.0001). It is concluded that the coronary bypass operation evokes a rapid decline in T3, which is not normalized by the TSH induced response of the thyroid gland, while the post-operative period is characterized by a \"low T3 state\". Those patients with low T3 concentrations prior to surgery demonstrate postoperatively a more severe degree of nonthyroidal illness (NTI). We could demonstrate that CPB induces a low T3 syndrome up to 3 days after surgery. There were no significant differences between CPB and OPCAB patients. "
    },
    {
      "exact_answer": "yes",
      "id": "532673c4d6d3ac6a34000009",
      "ideal_answer": "Perioperative administration of triiodothyronine increased cardiac output slightly and decreased systemic vascular resistance, but it had no effect on operative outcome. Parenteral triiodothyronine given after crossclamp removal during elective coronary artery bypass grafting significantly improved postoperative ventricular function, reduced the need for treatment with inotropic agents and mechanical devices, and decreased the incidence of myocardial ischemia. Raising serum triiodothyronine concentrations in patients undergoing coronary-artery bypass surgery increases cardiac output and lowers systemic vascular resistance, but does not change outcome or alter the need for standard postoperative therapy. We conclude that although widespread interest has been shown on the use of thyroid hormones in the perioperative period, and the effect of cardiopulmonary bypass on thyroid hormone metabolism widely studied, there is no substantial evidence to justify routine use of thyroid hormones in patients undergoing coronary artery bypass grafting. Treatment with GIK, T3, and GIK/T3 improves hemodynamic performance and results in reduced cTnI release in patients undergoing on-pump CABG surgery. No significant differences were noted in the pre and post CPB hemodynamics between the two groups for the most part of the study except that heart rate was increased in T3 group. "
    },
    {
      "exact_answer": "yes",
      "id": "53267871d6d3ac6a3400000a",
      "ideal_answer": "We conclude that although widespread interest has been shown on the use of thyroid hormones in the perioperative period, and the effect of cardiopulmonary bypass on thyroid hormone metabolism widely studied, there is no substantial evidence to justify routine use of thyroid hormones in patients undergoing coronary artery bypass grafting. There is no clear evidence at this point to support thyroid hormone replacement in the latter patients, and it may be potentially harmful. Raising serum triiodothyronine concentrations in patients undergoing coronary-artery bypass surgery increases cardiac output and lowers systemic vascular resistance, but does not change outcome or alter the need for standard postoperative therapy. Thus, there seems to be no sound justification for a routine use of T3 in patients undergoing open-heart procedures. Short duration postoperative iv T(3) therapy increases cardiac index and does not alter mortality. Although mild effects on myocardial performance may exist, we cannot recommend at this time the routine use of intravenous T(3) as an inotropic agent in patients undergoing coronary artery bypass graft surgery. Rather, we hold that T3 treatment of various surgical and other patients with nonthyroidal illness should be deferred until proof of its therapeutic efficacy is demonstrated. "
    },
    {
      "exact_answer": [
        [
          "Calcium"
        ],
        [
          "Ketonuria"
        ],
        [
          "Hyperglycemia"
        ],
        [
          "Clinical action"
        ],
        [
          "Reduction - action"
        ],
        [
          "Negative"
        ],
        [
          "Negative Chronotropy [PE]"
        ],
        [
          "Protoplasm"
        ],
        [
          "Djungarian Hamsters"
        ],
        [
          "Negative Inotropy [PE]"
        ],
        [
          "Rattus"
        ],
        [
          "chronotropic"
        ],
        [
          "Respiratory quotient"
        ],
        [
          "Central Minus"
        ],
        [
          "Inotropic agent"
        ],
        [
          "T prime"
        ],
        [
          "Extrinsic"
        ],
        [
          "Amines"
        ],
        [
          "Obese build"
        ],
        [
          "House mice"
        ],
        [
          "Depressed mood"
        ],
        [
          "Prompt"
        ],
        [
          "Intraperitoneal"
        ],
        [
          "Mass, a measure of quantity of matter"
        ],
        [
          "Bed Status - Isolated"
        ],
        [
          "Various patch test substance"
        ],
        [
          "Traumatic AND/OR non-traumatic injury"
        ],
        [
          "Consequence of"
        ],
        [
          "Homeostasis"
        ],
        [
          "Minimum"
        ],
        [
          "Etiology aspects"
        ],
        [
          "Ischemic"
        ],
        [
          "Conclusion"
        ],
        [
          "Injection of therapeutic agent"
        ],
        [
          "Resistant (qualifier value)"
        ],
        [
          "Hypothermia, natural"
        ],
        [
          "Administration procedure"
        ],
        [
          "Heart"
        ],
        [
          "Functional"
        ],
        [
          "Possible diagnosis"
        ],
        [
          "Observed"
        ],
        [
          "Increased"
        ],
        [
          "Metabolic:-:Point in time:^Patient:-"
        ]
      ],
      "id": "532c12f2d6d3ac6a3400001d",
      "ideal_answer": "Functional effects have been observed after administration of exogenous T(1)AM: in the isolated heart, a negative inotropic and chronotropic action was produced, and the resistance to ischemic injury was increased, possibly as a consequence of an action on intracellular calcium homeostasis. Intraperitoneal or central injection of 3-T(1)AM or T(0)AM into mice, rats, or Djungarian hamsters caused various prompt effects, such as metabolic depression, hypothermia, negative chronotropy, negative inotropy, hyperglycemia, reduction of the respiratory quotient, ketonuria, and reduction of fat mass. In conclusion, trace amines and thyronamines are negative inotropic agents. "
    },
    {
      "exact_answer": "yes",
      "id": "532c147bd6d3ac6a3400001e",
      "ideal_answer": "In conclusion, trace amines and thyronamines are negative inotropic agents. Their in vivo administration induces effects opposite to those induced by thyroid hormone, including lowering of body temperature. "
    },
    {
      "exact_answer": "yes",
      "id": "532c169ed6d3ac6a3400001f",
      "ideal_answer": "The integrin receptor activation by T4 may take a role in plasma membrane processes involved in the male reproductive system. ntegrins are heterodimeric structural components of the plasma membrane whose ligands include a large number of extracellular matrix (ECM) proteins. Recently, integrin αvβ3 has been shown to have a panel of previously unappreciated small molecule receptor sites for thyroid hormone and hormone analogues, for dihydrotestosterone, and for resveratrol, a polyphenol that has certain estrogen-like features. Rapid signaling via this plasma membrane binding site appears to be responsible for many nongenomic effects of thyroid hormones, independent of the classic nuclear receptors. "
    },
    {
      "exact_answer": "yes",
      "id": "532f09d2d6d3ac6a3400002b",
      "ideal_answer": "Rivaroxaban being excreted via kidney and liver, some precautions should apply in case of liver insufficiency. The novel oral anticoagulants (i.e., dabigatran, apixaban, rivaroxaban) all undergo renal metabolism to varying degrees, and hence dosing, efficacy, and safety require special consideration in CKD patients. However, all these agents undergo renal clearance to varying degrees, and hence dosing, efficacy, and safety require special consideration in patients with CKD. The new oral anticoagulants have relatively little data in patients with severe renal impairment, and all have an element of renal excretion. Dabigatran etexilate and rivaroxaban carry the highest risk due to a high degree of renal excretion, whereas the risk for apixaban, edoxaban and betrixaban seems lower. In the everyday practice it will be necessary to be very cautious in patients with impaired renal function, as all these drugs are eliminated by kidneys. Now new anticoagulant drugs(dabigatran and rivaroxaban) can become available. They have to carefully be used because they discharge from kidney and old aged patients have potential renal dysfunction. Rivaroxaban elimination is mainly renal, but also through faecal matter and by hepatic metabolism. Therefore, we have to learn how to use those drugs. "
    },
    {
      "exact_answer": "yes",
      "id": "53302bced6d3ac6a34000039",
      "ideal_answer": "ur findings suggest that the development of LCOS after congenital heart surgery is associated with decreased total and free T3, and increased IL-8 levels at 48 hours, and preoperative tT4 level is an independent predictor of LCOS. Low basal fT3 concentration can reliably predict the occurrence of postoperative AF in CABG patients. A relevant finding was that the days of post-operative hospitalization (10+/-3 days, means+/-S.D.) was inversely correlated with the slope of the recovery of T3 concentration (P\u003c0.001) or with the area under the plasma curves of T3 (P\u003d0.024,. time range 72-144 h) and the FT3/FT4 ratio (P\u003d0.037,. time range 72-144 h) during the post-operative period. "
    }
  ]
}